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ABSTRACT. 
This study reviews the literature in two major areas of 
Premenstrual Syndrome research. Firstly, the literature on 
the Premenstrual Syndrome itself is reviewed with the focus on 
such issues as syndrome definition, symptomatology, 
methodological problems, and etiological theories. Also 
outlined here are the hormonal events of the menstrual cycle 
with a review of the literature on premenstrual symptoms in 
relation to the menstrual cycle. The general conclusion here 
is that this area of premenstrual syndrome research has 
yielded confusing and often inconclusive results. Further 
well controlled research seems needed here. Secondly, the 
literature- on the more specific area of the Premenstrual 
Syndrome and hysterectomy is reviewed. Research into ovarian 
function and its methods of detection post hysterectomy is 
discussed, as is research into PMS and anovulation. The 
specific focus of this section is the review of the research 
of Backstrom, Boyle, and Baird (1981), and Beumont, Richards, 
and Gelder (1975) whose studies on PMS and hysterectomy have 
yielded contradictory results. It is concluded that both 
studies are beset with methodological problems making valid 
interpretation of their results difficult, and their 
application to clinical practice questionable. 
The aim of this study was to collect daily affective, 
somatic, and hormonal data from women who had undergone 
hysterectomy and who.believed they experienced PMS. Ovarian 
function was determined by the calculation of urinary 
pregnanediol levels. Spectral analysis was used to analyse 
the significance of this data. 
Of the thirteen subjects who finally took part in this 
I 
study, six showed significantly cycling mood and/or physical 
symptoms that were significantly related to the premenstrual 
phase of their cycle. The remaining seven subjects 
demonstrated significant cyclicity of mood and/or physical 
symptoms that were not related to their underlying hormonal 
cycle. It was concluded that there is some evidence to 
support the hypothesis that PMS can exist after hysterectomy, 
but more sophisticated research is suggested to further 
validate these findings. 
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SECT! ON ONE: LI TERATURE RE VI E W. 
CHAPTER ONE: THE PREMENSTRUAL SYNDROME. 
1 -1: I NTRODUCTI ON. 
For many years physical and affective fluctuations have 
been associated with the menstrual cycle. Clinical interest 
in these changes was initially aroused by the varied 
complaints women presented to their physicians, and it is 
Frank (1931), who is generally believed to have coined the 
term "Premenstrual Tension" (PMT) in what is marked as the 
first modern "scientific investigation" of premenstrual 
symptomatology. According to Frank, emotional symptoms of PMT 
consist of 
"a feeling of indescribable tension .... unrest, 
irritability ... and a desire to find relief by 
foolish and ill-considered actions." (Frank, 1931; 
p1054). 
Since 1931 however, there has been a huge amount of interest 
in this condition, which in turn has generated a vast but 
confusing body of literature. 
1-2: COMMON SYMPTOMS OF PREMENSTRUAL SYNDROMES. 
Table 1 -2: Common symptoms of Premenstrual Syndromes. 
AFFECTIVE 
Sadness 
Anger 
Anxiety 
Irritability 
Labile Mood 
NEOROVEGETA T! VE 
Insomnia 
COGNITIVE PAIN 
Decreased Concentration Headache 
Indecision 
Paranoia 
"Rejection Sensitive" 
Suicidal Ideation 
AUTONOMIC 
Na us e a 
Breast tenderness 
Joint and Muscle 
Pain 
CNS 
Clumsiness 
Hypersomnia 
Anorexia 
Craving for 
certain foods 
Fatigue 
Lethargy 
Agitation 
Libido Change 
Diarrhea 
Palpitations 
Sweating 
FLUID/ELECTROLYTE DERMATOLOGICAL 
Bloating 
Weight Gain 
Oliguria 
Edema 
Acne 
Greasy Hair 
Dry Hair 
Seizures 
Dizziness 
Vertigo 
Paresthesia 
Tremors 
BEHAVIOURAL 
Decreased Motivation 
Poor Impulse Control 
Decreased Efficiency 
Social Isolation 
Rubinow D. R. and Roy-Byrne P, (1984). "Premenstrual 
Syndromes: Overview from a Methodologic Perspective", 
American Journal of Psychiatry,~; p170. 
Abraham (1980) divided the symptoms into four subgroups 
(with the range encompassing anxiety, irritability, weight 
gain, breast tenderness, carbohydrate craving, depression, and 
withdrawal>, while Moos (1968; 1969) in an extensive study on 
menstrual cycle symptoms, derived eight symptom cluster scales 
of p a in, con c e n t rat ion, be h a vi 0 u r a 1 c han g e , aut 0 n 0 mi c 
reactions, water retention, negative affect, arousal, and 
control. 
Traditionally symptoms range from one or two to eight or 
nine in number, but can include any of the large combination 
of symptoms outlined and more besides. However, the inclusion 
of some reported symptoms in the literature is not entirely 
substantiated. For example, Moos (1968) originally included 
ani t e m abo u t .. c han g e i n eat i n g h a bit s'" i n his res ear c h , but 
found that it did not consistently locate with any of the 
other factors. Likewise, Silbergeld, Blast, and Noble (1971) 
Tailed to show any significant cyclical variation in appetite 
or food consumption. There has also been some disagreement in 
the literature regarding changes in sexual activity during the 
premenstrual phase of the menstrual cycle. Some have noted an 
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increase in sex drive during the first half of the cycle, 
pea kin gat 0 v u 1 at ion (B e ned e c k &. Rube n s t e in, 1 939; Moo s , 
1968), others have noted a mid-cycle increase in sexual 
unterest followed by a post ovulatory decrease (Kane, Lipton, 
&. Ewing, 1969), while Kinsey, Pomeroy, Martin and Gebhard 
(1953) found that 90% of American women experienced greater 
~exual arousal during the premenstrual phase. These 
conflicting reports are mainly due to the fact that the data 
from these studies were collected retrospectively through 
questionaires, and as a result are most likely to be 
reflecting remembered desire rather than actual significant 
changes in sexual interest or activity. 
1-3: METHODOLOGICAL CONSIDERATIONS. 
The existence of methodological flaws in design has by and 
large been responsible for the research literature dealing 
with this condition being confusing, inconsistent, and highly 
contradictory. In the last fifty years there has been a 
distinct lack of consensus over the definition of the 
syndrome, which has led to a significant variation between 
studies with regards to its cyclicity, severity, timing and 
course, although the emotional symptoms described by Frank 
have been consistently supported by a large body of research 
and clinical reports (Abraham, 1980, b); Dalton, 1980; 
Halbreich, Endicott, _Schacht, &. Nee, 1982; Israel, 1938; Moos, 
1969) . Additions to his list have also been made and an 
almost limitless number and variety of reported changes in 
mood states, behaviours, and somatic symptoms have since been 
connected with the premenstrual phase. Fur the r mo r e , sin c e 
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tension and stress are no longer considered the only major 
symptoms of the condition, it is now commonly referred to as 
the "Premenstrual Syndrome". (Indeed, in some cases tension 
may be overshadowed by other complaints or be entirely 
absent. ) 
The actual severity of the symptoms was initially rarely 
considered by many researchers. This meant, for example, that 
the symptom of depression was, and could be, applied to women 
who felt sad premenstrually and to women who felt suicidal at 
thi s ti me. However, the symptoms can range from mild to 
incapacitating, and the need for some form of differential 
grading of them has since been recognized and utilized by 
subsequent researchers, although to date, there is no 
internationally accepted scheme for symptom grading and 
classification (Abraham, 1980, b); Steiner, Haskett 8. Carrol, 
19813). 
As for the cyclicity of the symptoms, again the literature 
here is confusing. Some have defined PMS on the basis of its 
symptoms (Reid 8. Yen, 1981), while Dalton (19813) believes the 
timing of the symptoms to be more important than their actual 
presence, duration, or severity. Dalton (19813) stated that 
symptoms should occur regularly in the same phase of each 
menstrual cycle, and should then be followed by a symptom-free 
phase in each cycle. Indeed, both approaches have their place 
in the study of PMS. On the one hand, it is important to 
consider the presence or absence of symptoms when assessing 
the syndrome in order to avoid confusion with other 
cycle-related conditions such as dysmenorrhea, while on the 
other hand, Dalton's point is clearly an important one, given 
the large number and variety of these reported symptoms. Some 
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of the symptoms that make up the syndrome (for example, 
tension, anxiety, and headaches) are not uncommon ailments and 
do occur intermittently in women regardless of their cycle 
phase (Clare, 1981; Moos, 1969). 
Yet for the concept of the premenstrual syndrome to be of 
any clinical value, it is of the utmost importance to 
establish that there is a significant change (be it increase 
or decrease) in these symptoms during the premenstrual phase 
and that these changes are cyclic in nature, and do not occur 
regularly during other phases in the menstrual cycle 
( Crui kshank, 1983; Dalton, 1980). In spite of earlier 
findings to the contrary (Anderson, 1972; Paige, 1971; Parlee, 
1973; Rossi & Rossi, 1977; Swandby, 1980), the cyclical 
occurrence of these symptoms has been well established 
(Abraham & Hargrove, 1980; Hudson, 1985; Moos et al., 1969; 
0' Brien, Craven, Selby, and Symonds, 1979). 
The collection of accurate premenstrual data has also been 
a stumbling block in the study of the syndrome. For example, 
the term "premenstrual" can mean different things to different 
people- researchers and patients alike: Kramp (1968) included 
the last six days of the luteal phase and first two days of 
menstruation in his concept of premenstrual, Dalton (1964) 
encompassed four days prior to and four following the onset of 
menstruation, thereby allowing ~he separate condition of 
dysmenorrea to often be confused wi th PMS. However, Sutherland 
and Stewart (1965) postulated that the symptoms must, by 
definition, disappear with the onset of menses. Furt he rmore, 
many have collected data only once during the follicular 
phase, and once preme ns t ruall y (Ande rs e n, Larsen. Steens t rup. 
Svendstrup, & Nielson, 1977; Golub, 1976; Silverman. 
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Zimmerman, 8. Silverman, 1974). The findings from such data 
are of questionable validity since it assumes data collected 
in one cycle is representive of every cycle, and that the 
premenstrual phase may be predicted in advance of the cycle. 
However, symptoms within subjects may vary (in both number and 
severity) across cycles, and variations in the follicular 
phase can make predicting the luteal phase problematic even 
for women who ovulate and menstruate regularly. 
It is clear from this literature then, that the onset and 
timing of the premenstrual phase tends to reflect such things 
as the beliefs of the researcher about the length of this 
phase, the requirements of their particular experimental 
.' 
design, and designs employed by previous researchers. Yet 
physiological methods of determining cycle phase have become 
more refined and accurate. Developments in radioimmunoassay 
techniques allows the analysis of hormone levels from small 
quantities of serum or urine, and it is now possible to 
examine daily or hourly hormonal changes throughout the entire 
menstrual cycle (Metcalf, 1973). Research~~s can therefore no 
longer continue to make assumptions about cycle phase based on 
such techniques as the number of days past menstruation, or 
temperature change. Generally however, the premenstrual phase 
commences soon after ovulation during the luteal phase, and 
encompasses a time span of approximately eight to one days 
prior to menstruation. 
There are also such factors as experimenter expectancy 
effects, and the subjects' expectations about the purpose of 
the study that have been problematic, as have studies where 
subjects have been recruited from specific populations such as 
psychiatric wards, clinics, and gynecological surgeries whose 
findings have then been generalized to a normal population. 
Similarly, in the past, both the utilization of control groups 
and double-blind studies have been sparse. 
However, by far the two most serious methodological 
problems that have impeded the evaluation of PMS are the 
methods employed in the assessment of premenstrual 
symptomatology, and the methods used in its collection or 
recordi ng. Overall, much of the early research used general 
assessment techniques such as standard mood questionnaires and 
personality inventories, rather than ones specifically 
designed for menstrual cycle reseasrch. These types of 
asessments may not have been specific enough to assess whether 
the symptoms were in fact regularly occurring in the 
premenstrual phase of their menstrual cycles. It is therefore 
possible that unsuitable women may have been included in the 
samples, while suitable women may have been excluded. In 
order to standardize menstrual cycle symptom assessment Moos 
(1968) developed a Menstrual Distress Questionnaire (MDQ) 
which has since been used extensively. Steiner et a1. (1980) 
employed a modified MDQ and several psychiatric rating scales, 
Abraham (1980, a) utilized a 19-item questionnaire, and 
Halbreich et a1. (1982) developed the Premenstrual Assessment 
Form (PAn. This assessment form has categories for several 
different types of premenstrual mood, behaviour, somatic, and 
motor function changes, and allows for bi-directionality of 
symptom change. Yet even these assessment techniques have 
their methodological shortcomings. Moos' MDQ was initially 
retrospective in nature (but has since been modified), half 
his subjects were taking oral contraceptives, and nearly 10% 
were pregnant. His sample was therefore hardly representative 
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of the general population, and his findings are limited. 
Steiner et al. allowed only a very narrow definition of the 
syndrome by failing to include somatic symptoms in their 
assessment, thereby excluding from their sample many women 
with premenstrual symptoms such as weight changes, fluid 
retention and breast tenderness. Similarly, Abraham's scale 
was constructed without using standard psychometric 
procedures, resulting in questionable internal consistency and 
reliability. 
The validity of research findings have been further 
compromised due to the retrospective method of data collection 
employed by most of the early studies. This method usually 
involved the completing of assessment-type forms based on 
interviews, and the self report of symptoms experienced in 
previ ous cycles. Such responses are based on memory and as 
such, are influenced by such factors as expectation, and 
cultural beliefs and attitudes, and therefore may not be an 
objective measure of symptom change (Abplanalp, Donnelly, 8. 
Rose, 1979; Brooks-Gunn 8. Ruble, 1980; Rubi now 8. Roy-Byrne, 
1984) . Recently however, prospective methods of data 
collection have been employed by many researchers and, by 
obtaining daily reports of moods and physical symptoms over 
several cycles, have noted discrepancies between retrospective 
and prospective accounts of symptomatology (Abplanalp et al., 
1979; Brockway, 1975; May, 1976; Swandby, 1979; Vi la 8. Beech, 
1980). This lends support to the view that retrospecive data 
is of questionable value to those concerned with the diagnosis 
and treatment of PMS. 
Upon considering these methodological issues, it becomes 
clear that the findings in any piece of research on PHS must 
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be interpreted in the light of the strengths and weaknesses of 
the particular research method employed. 
1-4: The MENSTRUAL CYCLE. 
Cyclic ovarian function during the menstrual cycle 
involves the interaction between the ovaries and the 
hypothalamic-pituitary system. The interval between the first 
day of menstruation and the first day of the next menses 
constitutes one menstrual cycle. Cycle length varies from 
20-45 days, wi th the average length bei ng 28 days. Ovulation 
usually occurs mid-cycle, thus dividing the cycle into the 
follicular (pre-ovulatory),and luteal (post-ovulatory) phases. 
The length of the follicular phase ranges from 10-17 days, with 
an average of 12.6 days, while the length of the luteal phase 
is relatively fixed at approximately 14 +/- 2 days (Baird, 
Baker, McNatty, & Neal, 1975). Es t rogen, proges t erone, 
luteinizing hormone (LH),and follicle stimulating hormone 
(FSH) are the major features of the control system of the 
menstrual cycle. LH and FSH are both gonadotrophic hormones 
and are synthesized and released by gonadotropin-releasing 
hormone (Gn- RH) . 
hypot hal amus. 
Gn-RH itself is secreted by the 
At the beginning of the menstrual cycle during 
menstruation (the early follicular phase) estrogen and 
progesterone concentrations are low, and Gn-RH begins to 
release LH and FSH. In response to these increasing FSH 
levels several ovarian follicles, each containing an ovum, 
begin to develop. After 5-6 days one of these follicles 
develops more rapidly than the others, while inside, the 
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maturing ovum begins to release small quantities of estrogens 
into the blood stream. This is followed by a progressive 
increase in estrogen levels during the mid follicular, and a 
sharp increase during the late follicular phases, thereby 
inhibiting the further secretion of FSH. FSH levels then 
begin to fall which in turn leads to the regression of the 
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other developing ovarian follicles. Estrogen levels peak just 
before mid-cycle, and by exerting a positive feedback effect 
on the pituitary system, initiates a mid-cycle peak in LH. 
This LH peak then initiates ovulation by stimulating the 
growth of the ovarian follicle to the point where it 
eventually ruptures, releasing the mature ovum. 
Soon after ovulation FSH levels rise again, while estrogen 
and LH levels decline sharply, and the cycle enters the luteal 
phase. The ovum enters the fallopian tubes where 
fertilization is to occur and, whether fertilized or not, then 
moves on into the uterus. The follicle from which the ovum 
was released changes and becomes the corpus luteum. The corpus 
luteum then secretes progesterone, (causing basal body 
temperature to rise), and a small quantity of estrogen. 
Together they function to equip the uterus for a fertilized 
ovum and to inhibit the further release of LH and FSH. Luteal 
phase levels of LH and FSH then decline to a nadir three to 
four days prior to menses, and are generally lower than those 
in the follicular phase. The corpus luteum itself regresses 
and, within approximately 12 days after ovulation, ceases to 
function. Progesterone and estrogen are then no longer 
released, and levels begin to decline approximately four days 
prior to menstruation. FSH levels at this point begin to rise 
again, although LH levels remain low and relatively stable, 
1 1 
and if fertilization has not occurred, menstruation begins. 
As well as progesterone, estrogen, LH, and FSH, there are 
also other hormonal changes accompanying the menstrual cycle. 
Prolactin secretion is generally higher during the luteal 
phase than the follicular phase (Steiner & Carroll, 1977), 
aldosterone levels peak 9-18 days prior to menstruation then 
drop rapidly 3-4 days later (Katz & Romfh, 1972), and plasma 
angiotensin level are elevated in the luteal phase compared to 
the follicular phase (Sundsfjord & Aakvaag, 1978). 
1-5: THE MENSTRUAL CYCLE AND PREMENSTRUAL SYMPTOMS. 
The appearance of premenstrual symptoms has been closely 
linked to the luteal phase of the menstrual cycle, rather than 
specifically to ovulation (Backstrom et al., 1983; Brush, 
1977; Clare, 1979, a); Cruikshank, 1983; Haskett, Steiner, 
Osmun, & Carroll, 1988; Reid & Yen, 1981; Steiner & Carroll, 
1977). The symptoms usually appear soon after ovulation and 
gradually increase (in number and severity) in parrallel with 
corpus luteum development, and increasing progesterone levels. 
They then peak during the last five days of the luteal phase, 
past the point where estrogen and progesterone levels fall, 
and decrease rapidly with the onset of menstruation. 
More recently, Rubi now et al. (1986) reported on 
characteristic patterns of affective and somatic changes in 
women who did not experience PMS. While their research 
~upported the observations reported here, they also identified 
two different groups of non-PMS women, and hence, two 
different affective and somatic patterns. The first group 
consisted of women who presented with a retrospective history 
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of PMS, who subsequently failed to meet the confirmed 
prospective requirements of the syndrome. The second group 
were comprised of women who believed themselves to be 
asymptomatic who subsequently exhibited relatively stable mood 
patterns with small affective and somatic fluctuations. The 
former group however, exhibited more frequent mood changes, 
fluctuating from one extreme to another. Yet neither groups' 
affective and somatic fluctuations displayed any evidence of 
cyclicity, nor were they linked in any way to the premenstrual 
phase of the cycle. Although further research is necessary to 
validate these findings, Rubinow et al. have provided the 
clinician with useful information on the symptom profiles on 
non-PMS women, which may aid in the future selection of 
subjects for treatment and ~ontrol trials. 
CHAPTER TWO: THE ETIOLOGY OF PREMENSTRUAL SYNDROME. 
2-1: INTRODUCTION. 
The etiology of PMS, like its definition and diagnosis, 
has been the subject of much debate in the past fifty years. 
Theories are numerous and have been reviewed extensively 
(Backstrom, 1983; Clare, 1979; Steiner et al., 1977; Reid & 
1 3 
Yen, 1981). Generally there are two major theoretical stances 
in the et i 01 ogy of PMS: Psychol ogi cal and Bi ochemi cal. 
2-2: PSYCHOLOGICAL THEORIES OF PMS. 
2-2-1: Evolution and PMS. 
The evolutionary theory of PMS proposed by Rosseinsky and 
Hall (1974) postulates that PMS is an infertility indicator 
and has the evolutionary value of the propagation of the human 
race. However, while this is certainly a novel theory, the 
evidence to support it is, at best, extremely tenuous and can 
be questioned on a number of points. Their argument rests 
upon the hypothesis that there is a premenstrual increase in 
adrenalin which, in turn, causes premenstrual aggression. 
This then signals the woman that ovulation has recently 
occurred and she is now entering her infertile phase. Thus, 
by being hostile to her mate during this premenstrual 
infertile phase, and attentive at other non-premenstrual 
fertile times, the sexual desire of the mate is increased 
during those fertile periods, thereby increasing the 
probabilty of conception. Yet Rosseinsky and Hall provide no 
empirical support for this premenstrual increase in adrenalin 
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that is supposed to preclude this chain of events. Si mi larly, 
evidence of menstrual synchrony among cohabiting women is 
cited as evidence for the frustrated males not turning to 
other women during these infertile premenstrual times. While 
there is some evidence for menstrual synchrony (McClintock, 
1971), Rosseinsky and Hall admit that they have no statistics 
available on women cohabiting in mixed male and female groups. 
However they go on to speculate that such synchrony could well 
occur there. Again their argument rests upon speculation with 
no empirical data to support it. Furthermore, while they 
explain how PMS may have served some evolutionary purpose in 
prehistoric times, they fail to address the issue of its 
evolutionary value in the 1980' s. 
Finally, the implication of this theory is that PMS is 
both innate and ineradicable. Yet again, what evidence is 
there to support the concept of the genetic inheritability of 
PMS? This issue is too confused with social-expectation 
factors for a clear genetic component to be identified. 
Similarly, if PMS is ineradicable, this approach is of little, 
if any, clinical value in terms of the treatment of the 
syndrome, and offers no practical support to those women who 
find this condition debilitating. 
2-2-2: PMS and Personali ty. 
Much of the early work in this area took a psychoanalytic 
approach to PMS, regarding it as a reflection of unconscious 
conflicts about the acceptance of the menstrual function and 
the female role, while menstruation was seen to symbolize a 
lost child or feminity (Benedeck, 1952; Deutsch, 1944; Israel, 
1938). However, although the symptoms occurred prior to 
menstruation, this highly speculative theoretical position 
gives such a central role to menstruation itself, that it is 
probable that menstrual complaints could have become confused 
with the premenstrual complaints that constitute the 
premenstrual syndrome. 
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Some authors have regarded PHS patients as women with 
many family conflicts and who regard menses as a stressful and 
negati ve event (Paulson, 1961). others have built on this 
framework by relating such negative attitudes about 
menstruation to personality models (Levitt & Lubin, 1967, 
Paige, 1971). 
Furthermore, there are some authors of the view that PHS 
is somehow associated with deficiencies in a woman's 
personality growth and structure (Horton, 1950). Some even 
hint at the possibility of a relationship between menstrual or 
premenstrual complaints and a general "neurotic" tendancy 
(Coppen, 1965; Coppen & Kessel, 1963; Kramp, 1968; Levi tt & 
Lubin, 1967; Smith, 1976), and this viewpoint is, by and 
large, reflected in the methods used to study the association 
between PHS and personality. 
Such methods have included the analysis of admissions to 
psychiatric units in relation to the phase of the menstrual 
cycle at the time of admission (Dalton, 1959; Janowski, 
Gorney, Castelnouo-Tedesco, & Stone, 1969; Kramp, 1968; 
Torghele, 1957; Wakoh et al., 1960), the comparison of women 
with previously diagnosed affective disorders with a control 
group (Diamond, Rubenstein, Dunner, & Fieve, 1976), and the 
diagnosis of the syndrome based upon the administering of 
various personality tests (Coppen & Kessel, 1963; Rees, 1953; 
Taylor, 1979). 
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Both Rees (1953), and Coppen and Kessel (1963) found a 
significant positive correlation between PHS and neurosis. 
Irritability was seen by Coppen and Kessel as being the key 
psychological symptom of the syndrome, and found women who 
were irritable premenstrually were more likely to be irritable 
at other times during the cycle as well. Thus they saw these 
premenstrual symptoms as being an exacerbation of already 
existing personality traits that were related to neuroticism. 
Gough (1975) reported that women who showed signs of being 
eager to seek help and were self-doubting tended to report 
more premenstrual symptoms, whi Ie Coppen (1965) reported that 
there was also a high incidence of menstrual disorders among 
the neurotic patients he studi ed. Furthermore, when compared 
with controls, these patients complained more frequently of 
irritability, depression, and pain. Similarly, Gruba and 
Rorhbaugh (1975) confirmed these findings by reporting 
subjects' scores on the HHPI were significantly correlated 
with their subjective reports of cycle-related pain, behaviour 
change, negalive affect, and autonomic reactions. 
This literature then, has centered upon the association 
between affective disorders and PHS, and neurosis and PHS. 
The reason for this association lies in the fact that symptoms 
such as irritability, depression, tension, and swelling, are 
both premenstrual phenomena and are also significantly 
correlated with neuroticism. Yet this association is by no 
means absol ute. Golub (1976) could find no significant 
correlation between anxiety, a relatively stable baseline 
personality characteristic, and premenstrual anxiety or 
depressi on. Similarly, Rees (1953) also noted the presence of 
PHS in women with little or no evidence of instability in 
personality adjustment or neurosis, or in women with a 
predisposition to neurosis. Furthermore, he also found many 
women with severe neurosis who did not actually experience 
PMS. 
Thus it appears there is no simple relationship between 
PMS and personality in general, and neurosis in particular. 
The literature so far has had several crucial methodological 
flaws. Firstly there appears to be no uniform standardized 
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definition of "neurosis" and thus there is no way of measuring 
how it was assessed, or the way in which the presence or 
absence of premenstrual symptoms were established. Secondly, 
regarding psychiatric ill-health, there are few, if any, 
details provided of how the clinical diagnosis was made. 
Thirdly, there appears to be confusion between menstrual and 
premenstrual symptomatology, although Coppen and Kessel (1963) 
claimed menstrual pain was not associated with neuroticism but 
premenstrual pain was. Fourt hI y, t he range of premens t rual 
symptoms assessed were too limited and narrow. For example, 
the only psychological symptoms generally enquired about were 
irritability, depression, anxiety, and nervous tension. The 
only somatic complaints were headaches and swelling. No 
assessment was made of complaints such as food cravings, poor 
cognitive functioning, and poor coordination to name a few. 
Fifthly, there also appears to be sampling flaws in some of 
these studies. For example, Coppen's findings were based upon 
a sample of only 49 women and his controls used were matched 
for age and parity but not social class. Similarly, this 
sample consisted of both in-patients and out-patients but no 
mention is made of whether the patient's admission status 
affected the significance of the results. Reliable 
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conclusions regarding personality and PHS therefore require 
both a knowledge of the presence of menstrual and premenstrual 
symptoms, and the correlation of such symptoms with 
personality type in a sample derived from the general 
popul at ion. 
In a noteworthy study Taylor (1979), using the Eysenck 
Personality Inventory, Cattell's 16 Personality Factor 
questionnaire, and a daily symptom rating scale, found that 
there was a strong association between neuroticism and high 
levels of premenstrual symptoms. He also proposed a 
personality profile of high premenstrual complaint scorers, 
and although this research also has its methodological 
problems, it represe»ts a more thorough attempt to clarify the 
relationship between personality and PHS. 
On the basis of this literature then, it is difficult to 
assess whether personality traits in general, and neurotic 
traits in particular covary with the cyclical occurrence of 
premenstrual symptoms. The personality of the women may 
indeed be an important factor and personality instability may 
act as an intervening variable between severe neurosis and 
PHS. It is possible that there may be an etiologic factor 
common to both. However, it is also possible that this 
apparent association may be due to the same symptoms being 
common to both premenstrual and neurotic disorders. This 
could then have resulted in an artificially inflated pattern 
of correlations. 
2-2-3: Social-Expectation Theories of PHS. 
In recent times there has been a shift in emphasis away 
from the personality theories of PHS to focus on the extent to 
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which PMS is mediated by beliefs and attitudes about 
menstruation and a woman's perception of the menstrual cycle. 
Within a social-learning framework, both the premenstrual 
phase and menstruation are viewed by many cultures as a 
negative and often debilitating emotional and physical event. 
Proponents of these theories postulate then, that social 
factors such as emotional conditioning, cultural beliefs and 
stereotypes may aggravate the severity of the premenstrual 
symptoms, thereby exacerbating the experience of the syndrome. 
Yet research on the influence of such attitudes and 
beliefs on PMS is actually sparse. Paulson (1961), using a 
180-item Menstrual Attitude Inventory, no~ed that many women 
with severe PMS also had mothers who experienced PMS and 
dysmenorrhea, and concluded from this that it may well be 
possible for attitudes about menstruation to be transmitted 
from one generation to the next. He also reported a ' 
significant correlation between attitudes towards menstruation 
and the degree of symptoms reported. The greater the 
severity, the greater the negative attitudes towards menses. 
Parlee (1974) found that both male and female subjects 
attributed negative emotions in premenstrual women to the 
phase of the cycle, whereas any positive emotions were 
attributed to situational factors. Kelley's covariation 
principle proposes that symptoms that covary with a particular 
cycle phase will tend to be attributed to that phase, 
especially if they do not covary with other plausible causes 
(Kelley 1973). Women may therefore attribute their symptoms to 
their menstrual cycle rather than to the situations that may 
have induced them. This then sets off an attribution pattern 
linking their negative mood swings (for example) to the 
approach of menstruation (Compos & Thurow, 1978). 
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In order to demonstrate the sensitivity of premenstrual 
mood changes to expectations and beliefs, Ruble (1977) altered 
subjects' perceptions of their cycle phase by convincing them 
that they were either in their premenstrual phase (with menses 
due in one or two days), or in their intermenstrual phase 
(with menses due in seven to ten days). By rating the extent 
to which they had experienced any menstrual symptoms in the 
last day or two, those assigned to the premenstrual group 
reported significantly higher symptom ratings for water 
retention, pain, change in eating habits, and sexual arousal 
than those assigned to the intermenstrual phase. However, 
there was no significant difference between the groups for 
negative affect. From this Ruble concluded that learned 
associations or beliefs may lead a women to exaggerate what 
she is actually experiencing or to be more sensitive to 
naturally fluctuating bodily states (such as water retention 
and weight change) when she believes she is premenstrual. 
Yet this literature has so far also been beset with 
methodological issues that cast some doubt on the strength of 
these conclusions. For example, Paulson's Attitude Inventory 
was utilized by few researchers, and never submitted to 
ri gorous testi ng (Paulson, 1961). Its validity therefore has 
not been established. Similarly, while limited support was 
found for the covariation principle (Compos & Thurow, 1978), 
it did not hold for the symptoms of depression, irritability, 
and tension. For covariation to be perceived then, there must 
be some cue that distinguishes between the cycle phases, and 
that these symptoms can frequently occur during other phases 
of the cycle, could have resulted in them not actually being 
perceived as covarying with anyone particular phase in the 
c yc 1 e. Furthermore, all were based upon data obtained 
retrospectively through questionnaires and self reports. 
Thus, women with no or minimal symptoms may have exaggerated 
when reporting retrospectively, and similarly, women who were 
unaware of the temporal relationship between their affective 
and somatic fluctuations and their menstrual cycle may have 
underestimated them, or not reported them at all. However, 
while awareness of a particular phase of the menstrual cycle 
may alter a woman's perception of, or sensitivity to, PMS, it 
has already been established that retrospective reports of 
menstrual mood variations often fail to match actual 
prospective reports of mood at different times during the 
cycle (Abplanalp et al., 1979; May, 1976; Swandby, 1979). 
21 
The effects of placebo treatments on premenstrual symptoms 
in prospective studies are perhaps one of more sound methods 
of assessing the role of psychosocial factors in PMS. Marked 
placebo effects have been noted, especially in relation to 
premenstrual irritability, and depression (Cullberg, 1972; 
Goldzieher, Moses, Averkin, Scheel, 8. Taber, 1971). Metcalf 
and Hudson (1985) noted a significant placebo response for 
mood related PMS only in eight out of thirty one women who 
were observed for six menstrual cycles. However, they also 
noted that there were 13 women who experienced premenstrual 
symptoms in every cycle, and a total of 21 who had PMS in five 
of the six cycles and were thus placebo resistant. Given such 
a finding, it cannot be concluded that psycho-social factors 
s u c has ex pee tat ion, c u 1 t u r alb e 1 ie f s , and s t ere 0 t y pes a 1 0 n e 
are responsible for the manifestation of premenstrual 
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symptoms, although it does lend support to the earlier reports 
that their interpretation and expression are sensitive to such 
factors. 
2-2-4: Conclusions. 
In spite of the methodological problems that have hampered the 
research on the psychological theories of PMS, there can be 
little doubt that both personality and psychosocial factors 
are implicated in its etiology. However, as yet, there is no 
conclusive evidence to suggest that these factors alone are 
responsible for the condition. 
2-3: BIOCHEMICAL THEORIES OF PMS. 
These theories relate premenstrual symptoms to a set of 
c ovaryi ng bi oc he mi cal i mbal ances, def i c i e nci es, or 
fluctuations. 
2-3-1: Estrogen/Progesterone Theories. 
Estrogen and progesterone regulate the menstrual cycle 
and, since the symptoms are so closely related to this cycle, 
the role of these two hormones in the etiology of PMS has 
often been addressed (Abraham, 19813, a; Dalton, 1959; Frank, 
1931; Morton, 19513). Indeed, Frank (1931) first proposed that 
PMS was the result of excessive estrogen levels in the blood. 
Since then theories have hypothesized 1: an 
estrogen: progesterone ratio imbalance, 2: an excessive and/or 
deficient production of one or both hormones, 3: an abnormal 
sensitivity to estrogen and 4: a response to the withdrawal 
from either estrogen or progesterone as possible causes of the 
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premenstrual symptoms. 
2-3-1 -A: Progesterone Therapy for PMS. 
The rationale for the use of progesterone in the treatment 
of PMS was first advocated by Israel (1938) who postulated 
that premenstrual symptoms were caused by the defective 
functioning of the corpus luteum, resulting in a progesterone 
deficiency. others have endorsed this idea by adding that 
this deficiency in turn results in estrogen being inadequately 
countered or opposed by progesterone. Excessive estrogen 
levels can cause fluid retention, and breast complaints, and 
the CNS effects through accumulating levels in the limbic 
system (Backstrom 8. Mattson, 1975; Israel, 1938; Morton 1950). 
Similarly, progesterone therapy was eagerly supported by 
Dalton (1977) who found lower levels of plasma progesterone 
during the luteal phase in PMS patients when compared to 
controls. 
However, subsequent research has yielded inconsistent and 
contradictory evidence to support this premise. While 
Dalton's findings were supported by some (Backstrom, Wide, 
Sodergard, 8. Carstensen, 1976; Munday, Brush, 8. Taylor, 1981), 
there were also others who failed to establish superiority 
over placebo when treating a variety of common premenstrual 
symptoms with progesterone (Andersch, Abrahamsson, Wendestam, 
Ohman, 8. Hahn, 1979; Sampson, 1979; Smith, 1976; 0' Brien, 
Selby, 8. Symonds, 1 Q80), although they did note that some 
women with PMS had lower plasma progesterone levels compared 
to non-PMS patients. Similarly, many have also failed to find 
any evidence of deficient corpus luteum functioning Andersch, 
Hahn, Andersson, 8. Isaaksson, 1978; Backstrom et al., 1983; 
Bickers & Woods 1951; Greenblatt, 1940). 
2-3-1 -B: Oral Contracepti ves. 
Oral contraceptives have been found to significantly 
decrease the severity of some premenstrual symptoms (Herzberg 
& Coppen, 1970; Hears & Grant, 1962; Hoos, 1969), thereby 
appearing to support the hypothesis that estrogen and 
progesterone levels may be implicated the etiology of PHS. 
However, these studies were uncontrolled, and may have 
actually confused premenstrual symptomatology with 
dysmenorrhea, a condition clearly relieved by this type of 
therapy (Cullberg, 1972). Cullberg (1972) identified a small 
group of women whose symptoms were relieved by highly 
progestogenic oral contracepti ves, and were made worse by 
highly estrogenic ones. Horris and Udrey (1972) in a double 
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blind controlled study showed no significant difference in the 
premenstrual symptomatology of oral contraceptive and non oral 
contraceptive users at all. Again little agreement regarding 
the effectiveness of this type of therapy on premenstrual 
symptoms has been reached. 
2-3-1-C: Estrogen: Progesterone Ratio. 
Backstrom and Carstensen (1974) noted women exhibiting 
premenstrual anxiety had depressed progesterone and raised 
estrogen luteal levels, and an estrogen: progesterone ratio 
level significantly elevated in the last 3-6 days of the 
cyel e. Similarly, Abraham (1980, a) found decreased luteal 
estrogen: progesterone ratios in women with premenstrual 
anxiety, irritability, and nervous tension, but increased 
ratios in women with premenstrual depression. It has also been 
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suggested that premenstrual symptoms were provoked by 
progesterone withdrawal, since symptom severity peaks at a 
time when both estrogen and progesterone levels are falling 
(Greene 8.. Dalton, 1953; Kutner 8.. Brown, 1972), while 
Somerville (1972) postulated that estrogen withdrawal could be 
implicated in the onset of premenstrual migraines. 
Yet again research findings in this area are unclear and 
inconclusive. During the follicular phase PMS patients are 
generally feeling at their best, and are symptom free. Yet 
estrogen levels during this phase are much higher than 
progesterone levels, and when they falloff rapidly at 
ovulation, migraines, if Somerville is correct, should also be 
expected to occur at this time. Similarly, while the late 
luteal phase estrogen: progesterone ratio may be changing and 
falling the premenstrual symptoms are already present and well 
established by the time this occurs, leaving it unlikely that 
PMS is due to these changing ratios alone, although it is 
possible that the symptoms may be aggravated by them. 
2-3-2: Prolactin and PMS. 
Raised levels of the pituitary hormone prolactin (PRL) has 
also been suggested as an etiological factor in PMS (Carroll 8.. 
Steiner, 1978; Horrobin, 1973) and have been reported in PMS 
patients (Brush, 1977; Halbreich, Assael, Ben-David, 8. 
Bornstein, ·1976; Kullander 8.. Svanberg, 1979). Yet the 
treatment of premenstrual symptoms with a PRL suppressant, 
bromocriptine, has at best, yielded limited and indirect 
support for this theory. 
In a double-blind trial, Benedeck-Jaszmann and 
Hearn-sturtevant (1976) demonstrated the superiority of 
bromocriptine over placebo in alleviating premenstrual mood 
disturbances, edema, breast tenderness, and weight gain, and 
subsequently claimed they had discovered the 
key to the etiology of the syndrome. However, this study was 
comprised of women attending an infertility clinic, and were 
thus hardly representative of the general population. Graham, 
Harding, Wise, and Berryman (1978), reported a significant 
improvement in affective symptoms compared with placebo, and 
decreased breast tenderness and weight gain, although 
treatment was administered during two luteal phases and data 
collected during the last five days of each cycle only. The 
report of Andersch et al. (1979) of beneficial effects from 
bromocriptine on premenstrual irritability and breast symptoms 
was confounded by the absence of a placebo trial, while 
Elsner, Buster, Schindler, Nessim, and Abraham (19813) found 
bromocriptine to be superior to placebo on only three of the 
eight premenstrual symptoms monitored. Similarly, Andersen et 
al. (1977) noted the only symptom significantly improved 
through this therapy was mastodynia (breast pain). 
Indeed, this was the one consistent finding from all of 
these bromocriptine trials, in spite of their methodological 
problems. However, it can not be concluded from this 
literature that it was bromocriptine's effects on PRL levels 
that brought this about. For, al though bromocri pti ne was 
shown to reduce PRL levels, there was no evidence to suggest 
that they were abnormally elevated to begin with. Recently 
Backstrom and Aakvaag (1981) found no PRL level difference 
between PMS patients and controls, nor were the levels cited 
by Brush (1977), Halbreich et al. 1976, or Kullander and 
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Svanberg (1979) outside the "normal" range. 
Bromocriptine treatment then, has shed very little light 
on the role of PRL in the etiology of PMS, although as a 
dopamine agonist, its apparent therapeutic effects on 
mastodynia may well be mediated through direct dopaminergic 
action at central nervous and peripheral sites. Further 
research is neccessary before such a relationship can be 
established. 
2-3-3: Nutritional Theories of PMS. 
Generally it is believed that premenstrual symptoms may be 
the result of a deficiency in some nutrients causing a 
hormonal imbalance and diminished stress threshold (Abraham, 
1980, a, b; Block, 1960; Nicholas, 1973; Pagani .. 1952; von 
Klei n, 1954). On the basis of this, many nutritional theories 
of the premenstrual syndrome have been proposed, while almost 
every vitamin has been recommended at some time during the 
past fifty years as treatment. 
Abraham and Hargrove (1980), and London, Sundaram, and 
Goldstien (1982) found vitamin E significantly reduced 
mastodynia, while Nicholas (1973), and Michaelson, Juhlin, and 
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Valquist (1977) in double blind trials, noted that vitamin A 
and zinc supplements alleviated premenstrual oily skin and 
acne. Abraham and Hargrove (1 ~_80) also postulated that a 
magnesium deficiency could be responsible for premenstrual 
anxiety, tension, and_ irritability. Previously Nicholas 
(1973) had noted a reduction in nervous tension, mastodynia, 
and weight gain when treating PMS patients with magnesium. 
However, the rationale behind. this theory and treatment rests 
upon a tenuous link between stress, carbohydrate craving, and 
a magnesium deficiency. There are also reports in the 
literature of success in the treatment of PMS with vitamin A 
(Argonz 8. Abinzano, 19513; Block, 19613; Michaelson et al., 
1977; Nicholas, 1973; Pagani, 1952; von Klein, 1954). I twas 
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postulated by Argonz and Abinz~no (1952) that deficient 
estrogen metabolism may be corrected by vitamin A, while 
Pagani (1952) thought it prevented thyroid hyperfunction. Von 
Klein (1954) on the other hand, postulated that vitamin A had 
direct anti-estrogenic and diuretic properties which thereby 
alleviated premenstrual symptoms. 
The use of pyridoxine (vitamin B6) has probably been the 
most common vitamin treatment for PMS to date. Its use was 
first advocated because it was postulated that PMS resulted 
from a B-Complex deficiency causing aberrant estrogen 
metabolism (Biskind, Biskind, 8. Biskind, 1944). PMS patients 
were reported to respond well to vitamin B therapy, following 
which, estrogen levels returned to 'normal' A second line of 
reasoning behind the treatment of PMS with pyridoxine came 
through the discovery that it acts as a coenzyme in the 
biosynthesis of dopamine and serotonin. These brain 
monoamines have been implicated in the modulating of memory, 
mood, behaviour, and motor coordination. Therefore a 
deficiency in B6 leading to a deficient biosynthesis of 
serotonin from tryptophan and impaired dopaminergic function, 
could well be an etiologic factor in the mood changes 
associated with PMS (Adams, Wynn, Seed, 8. Folkard, 1974; 
Andersch et al., 1978; Judd 8. McMurdo, 1960; Rose, 1978). 
FU1'thermore, there has been immense interest in its use, and a 
vast body of literature to attest to its therapeutic value. 
(Abraham 8. Hargrove, 1980; Barr, 1984; Snider 8. Dietman, 
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1974). 
However, in spite of this, a large gap between theory and 
supporting evidence is still apparent. The magnesium 
deficiency and vitamin A hypotheses and treatments are, by and 
large, unsubstantiated, and many of these treatments, although 
amenable to double blind placebo trials, were not well 
controlled. Similarly, the vitamin B6 and B-Complex 
rationale was challenged as early as 1948 with the discovery 
of women with apparently normal estrogen metabolism yet 
suffered from a severe vitamin B deficiency (Zondeck & 
Brezezinski, 1948). In a double blind placebo controlled 
study, Stokes and Mendels (1972) failed to establish the 
superiority of vitamin B6 over placebo in relieving 
premenstrual symptoms, while subsequent studies have also 
failed to reveal any consistent or significant dopaminergic 
effects of B6 (Canales, Soria, Zarate, Mason, & Molina, 1976; 
DeWaal, Stevn, Harms, Slabber, 8. Pannell, 1978; Husami, 
Idriss, Jewelewicz, Ferin, & Vande-Wiele, 1978; Peters, 
Zimmerman, 8. Breckwoldt, 1978; Tolis, Laliberte, Guyda, 8. 
Naftolin, 1977). 
2-3-4: Fluid Retention. 
A great deal of attention has focused on the possible 
etiological factors of premenstrual fluid retention, and the 
effectiveness of diuretic treatments for symptoms related to 
t hi s. However, when administered in controlled double-blind 
trials, diuretics have failed to significantly alter weight or 
total body water, thereby afforrling no significant relief from 
the symptoms (Reid & Yen, 1981). Similarly, some have failed 
to establish a cyclical pattern of premenstrual weight gain or 
body water and sodi um changes (Andersch et a1., 1978; Mattson 
and von Schoutz, 1974), while others, with the exception of 
premenstrual edema, could find no significant relationship 
between fluid retention and the severity of the premenstrual 
symptoms (Appleby, 1960; Golub, Menduke, & Conley, 1965). 
Such studies therefore, do not support the advocacy of 
diuretic treatment for PMS based on the premise that fluid 
retention plays a major role in the manifestation of 
premenstrual symptoms. 
2-3-5: The Renin-Angiotensin-Aldosterone (RAA) Axis. 
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Janowski, Berens, and Davis (1973) postulated on the basis 
of the relationship between body weight and negative affect, 
that the underlying mechanism in the etiology of PMS was the 
RAA axis. However, in view of the doubt in the literature 
reviewed here on the role of fluid retention in PMS, this has 
not been established with any degree of certainty. 
2-3-6: Endogenous Opiates and PMS. 
Recently, Reid and Yen (1981) have proposed that cyclical 
changes in endogenous opiate activity may be the 
neuroendocrine event underlying the manifestation of 
premenstrual symptoms. This hypothesis cites the abnormal 
release of, or heightened sensitivity to, the neuropeptides 
beta-endorphin and alpha-melanocyte stimulating hormone during 
the luteal phase as causing an excessive exposure to, and 
subsequent withdrawal from, endogenous opiate peptide (EOP) 
activity, thereby triggering the premenstrual symptoms. 
Neuropeptides, by their ability to alter neurotransmitter 
activity, can cause mood and behaviour changes, as well as 
affecting pituitary hormones such as PRL and vasopressin 
release. 
Increased EOP activity during the luteal phase is 
associated with increased appetite, and the inhibition of the 
biogenic amine systems, thereby decreasing the release of 
dopamine or norepinephrine, and causing fatigue and 
de pres si on. Raised EOP levels are also thought to inhibit 
31 
prostaglandin-E1 (PG-E1) in the bowel, and decrease muscular 
propulsive activity, causing constipation and fluid retention. 
Acute withdrawal from EOP activity, and the return to normal 
neurotransmission of the biogenic-amine systems is 
hypothesized to occur during the late luteal phase, and 
coupled with the possibility of a slowly acquired sensitivity 
to this normal neurotransmission, results in rebound 
hyperactivity, leading to premenstrual anxiety, irritability, 
and aggression. Increased PG-E1 activity following this 
withdrawal results in premenstrual diarrhea. Furthermore, 
variations in the degree or duration of this EOP exposure, and 
the rapidity of withdrawal are thought to account for 
differences in the severity of PMS from one month to the next 
(Reid & Yen, 1981; 1983). 
As evidence for this position Reid and Yen (1983) draw 
parrallels between premenstrual symptoms and those commonly 
evoked by exogenous opiate exposure and wthdrawal. 
Constipation and diarrhea are common features of opiate 
exposure and withdrawal (Coupar 1978), as is dopaminergic 
hyperfunction and the resulting hostile and irritable 
behaviour' (Gianutsos & Lal, 1978; Reid 8. Yen, 1981; Schwartz, 
Pollard. Llorens et al., 1978). Furthermore, the decreased 
neurotransmission by biogenic amines is also implicated in 
32 
depression (Adolphe, Dorsey, & Napoliello, 1977; Van Praag, 
1978). Further support is provided by research into the 
effects of the opiate receptor antagonist naloxone. By 
blocking endogenous opiate peptides, this drug can produce 
premenstrual type symptoms (Cohen et al., 1981; Quigley & Yen, 
19813). However, apart from Peck's study (1982), no 
confirmation has been provided for these comparisons and 
conclusions, and evidence of abe rant neuropeptide activity in 
PMS patients and its underlying mechanisms is yet to be 
demons t rated. Yet it is nevertheless, a plausible theory, and 
should not at this stage be discounted since further naloxone 
studies may provide the necessary empirical evidence. 
2-3-7: Summary. 
Again, given the methodological problems already addressed it 
is no surprise that the literature on these biochemical 
theories of PMS is also in a state of disarray and confusion. 
These issues have diminished the strength of the etiological 
conclusions derived from the treatment literature, and to 
date, none of these treatments or theories have withstood 
double blind trials. 
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CHAPTER THREE: PREMENSTRUAL SYNDROME AND HYSTERECTOMY. 
3-1: PMS AND ANOVULATION. 
A finely integrated pattern of hormone secretions from the 
ovary and hypothalamic-pituitary systems is necessary for 
regular ovulation. As has already been mentioned, the ovary 
controls the timing of the cycle, and appears largely to be 
endogenously driven. However, variations altering this rhythm 
can spontaneously occur in a normal menstrual cycle. This 
mos t freq uentl y occ urs for e xampl e, foIl owi ng pregnanc y, 
during early and late productive years, and during lactation. 
Ovulation can also be affected by stress, and major dietary 
and weight changes. Anovulation and amenorrhea can have a 
number of origins although it is beyond the scope of this 
thesis to review each possible cause. Generally, anovulation 
is due to acyclic gonadotrophin release resulting in the lack 
of corpus luteum development, and the absence of menstruation 
(Rebar, 1983; Schneider 8. Leyendecker, 1983). However, there 
is little evidence to suggest whether women with PMS 
experience their symptoms during anovular cycles, and few 
studies have been undertaken to investigate this. 
Adamopol ous, Lorai ne, Lunn, Coppen, and Dal y (1972) ina 
study of 8 chronic PMS patients, observed seven anovular 
cycles out of fifteen, concluding that PMS could exist in the 
absence of ovulation. Similarly, Andersen et al. (1977) 
reported the presence of premenstrual complaints in two 
anovular control cycles. On the other hand, Backstrom et al. 
(1983) reported no cyclical mood changes, and only a slightly 
stastically significant premenstrual increase in breast 
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tenderness in three women over five anovular cycles. Magyar, 
Boyers, Marshall, and Abraham (1979), after moni tori ng 40 
women, concluded that an indication of an ovulatory cycle were 
the presence of regular cycles, and consistent premenstrual 
symptoms. 
Again the conflicting evidence can be put down to 
methodological issues. Adamopolous et al. (1972) estimated 
ovulation on the basis of pregnanediol levels, yet gave no 
specific criteria by which ovulation (or rather, anovulation) 
was determi ned. Nor was any mention made of whether the 
symptoms were prospectively recorded, and seven of the eight 
subjects indicated the presence of an underlying psychiatric 
bac kground. Their symptoms could easily have been a function 
of this rather than related to the menstrual cycle. 
Similarly, Andersen et al. (1977) also failed to elaborate on 
the criteria by which ovulation was determined, nor were 
details supplied on the type of premenstrual complaints that 
were present. However, if premenstrual symptoms do in fact 
fail to appear during anovular cycles, then relief from the 
syndrome would be afforded by suppressing ovarian activity. 
Studies on the effects of oral contracepti ves on PMS , as 
has already been discussed, have yielded conflicting results. 
More recently however, attention has focused on the effects of 
antigonadotrophic agents which suppress ovarian activity. 
These agents act by preventing the mid-cycle LH surge, thereby 
preventing follicle growth and subsequent ovulation. Post 
ovulatory FSH levels are also inhibited, and since there was no 
follicular development, there is also no corpus luteum or 
menstruation. Day (1979) found Danazol to be effecti ve in 
treating PMS, whereas Mansel, Wiseby, and Hughes (1982) found 
that it was superior to placebo only in the treatment of 
breast tenderness. Furt hermore, the y coul d find no e vi dence 
of a temporal relationship between the symptoms and cycle 
phase during the administering of Danazol, and its side 
effects outweighed any therapeutic value it may have held. 
Preliminary results from the administration of Buserelin 
revealed that premenstrual symptoms were aggravated if 
initially administered during the follicular phase (Bancroft, 
Boyle, Davidson, Gray, & Fraser, 1984). However, its 
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therepeutic effects were not evident until the second month of 
treatment, and then was only effective in controlling PMS in 
some women. Similarly, Muse, Cetel, Futterman, & Yen (1984) 
noted a marked attenuation of premenstrual symptoms with the 
admi ni s t ra t i on of a GnRH agoni st. Aft er one mont h, bot h 
physical and affective symptoms had decreased in severity to 
follicular phase levels. 
Research into the effects of naturally occurring and 
medically induced anovulation on PMS is, at present, in its 
early stages, and is marked by a lack of clear evidence one 
way or the other. With regards to naturally occurring 
anovulation, such research is hampered by the necessity to 
establish the mechanisms leading to its absence. Furthermore, 
it is important that these be considered when deriving 
conclusions about the hormonal fluctuations and apparently 
covarying premenstrual symptoms during these anovular cycles, 
since it is possible that these symptoms may in fact be a 
function of the mechanisms underlying the anovulation itself. 
However, by medically inducing anOVUlation in normally 
menstruating PHS patients and controls, the clinician will be 
able to control the ovarian cycle, and then evaluate in a 
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placebo-controlled fashion, both the effects of this 
anovulation, and the effects of exogenously administered 
steroids (such as estrogen), on the premenstrual symptoms. 
Such a technique may be of great practical interest to all 
concerned with menstrual research, and if pursued, may provide 
valuable information on the etiology of PMS whatever the 
outcome. 
3-2: PMS AND HYSTERECTOMY. 
The literature has so far suggested that the presence of 
ovar ian ac t i vi t y, t he corpus I ut e um, and accompanyi ng hormonal 
events are all implicated in the etiology of PMS. As well as 
this, psychological factors such as personality, cultural 
beliefs, and expectations about menstruation can influence a 
woman's interpretation and reporting of her symptoms. In an 
attempt to control for the expectation effects regarding 
awareness of cycle phase and approaching menstruation, and to 
gain further evidence of the role of ovarian steroids in"PMS, 
attention has recently focused upon the presence and/or 
persistence of premenstrual symptoms in women who have 
undergone a simple hysterectomy, whose ovaries have remained 
intact. 
Beumont, Richards, and Gelder (1975) in a study of seven 
hysterectomized women, found no significant differences in 
symptoms between two phases of the menstrual cycle, although 
they showed evidence of ovarian function. However, while data 
was collected prospectively, this was only done so for 
approximately thirtyfive days. This barely covers one 
menstrual cycle, hardly providing adequate information about 
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the persistent cyclical mood and somatic changes that 
consti tute PMS. Similarly, no mention was made of whether 
these women had ever experienced cyclical premenstrual changes 
prior to their hysterectomy. If they had not, there was no 
reason to expect that they would do so after hysterectomy. If 
however, they had retrospectively reported having experienced 
PMS prior to their hysterectomy, these negative results could 
have been due to the well documented inadequacies of 
retrospectively selected subjects. No firm conclusions about 
the role of expectation, or hormonal influences in the 
etiology of PMS can therefore be drawn from this research. 
Nor on the basis of these findings, can one speculate on the 
existence of premenstrual symptoms post hysterectomy. 
Backstrom, Boyle, and Baird (1981) studied seven women who 
had been prospectively diagnosed as experiencing PMS and who 
had then undergone a hysterectomy. Dai.ly records of moods and 
physical symptoms were recorded, and ovulation was indicated 
from the change in excretion of pregnanediol and total 
estrogen. They noted the persistence of the cyclical affective 
and physical symptoms of PMS in the presence of ovarian 
function in these women. The presence of these symptoms, 
although less severe than prior to their hysterectomy (but not 
significantly so), led Backstrom et al. (1981) to conclude 
that the presence of the uterus was neither necessary for 
ovulation, nor for the formation or regression of the corpus 
luteum. 
However, like Beumont et al. (1975), these findings must 
be interpreted in the light of several methodological 
consi deI'ati ons. Firstly, diagnosis prior to hysterectomy was, 
with the exception of one subject for whom a menstrual history 
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was available, made on the basis of data obtained from one 
cycle only. While it was fortunate that all of these subjects 
ovulated during that cycle, their ages ranged from thirty to 
for t yni ne ye ars. Some of these subjects were therefore in an 
age group where, approachi ng menopause, anovular cycles are 
common. Secondly, after the hysterectomy, data was collected 
over two cycles for four subjects, and over only one cycle for 
the remaining three subjects, making a total collection period 
of two to three cycles for the entire study. This is hardly 
sufficient time to assess a) the existence of cyclical 
premenstrual symptoms prior to the hysterectomy, and b) their 
persistence (and any changes in severity etc.) post 
hysterectomy. Thirdly, the collection of the hysterectomy 
data began immediately after surgery, allowing little time for 
recovery from any post operative trauma. Simi I a r I y, reI i e f 
from fibromyoma and menorrhagia afforded by the surgery could 
well have resulted in the subjects being better able to 
tolerate their premenstrual symptoms, which could account for 
reported changes in symptom severity. 
3-3: OVARIAN FUNCTION POST HYSTERECTOMY. 
The continued functioning of the ovaries after 
hysterectomy has now become an important concern to those who, 
like Backstrom et al. (1981) and Beumont et al. (1975), take 
the study of the premenstrual syndrome into this realm. 
SimilarlY, the prediction of cycle phase in the absence of 
menstrual markers is also crucial in this area of research. 
It has been demonstrated that the uterus plays an 
important role in the functioning of the corpus luteum in some 
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non-human species (Anderson, Bland, 8. Melampy, 1969; Fischer, 
1967; Neill, Johansson, 8. Knobi, 1969), and it is postulated 
that such functioning is due to the secretion by the uterus of 
luteolysin. (Anderson, Neal, 8. Melampy, 1962; Gardner, First, 
8. Casida, 1963; Hansel, 1966; Short, 1964). Although 
hysterectomy is known to prolong the luteal function in guinea 
pigs (Loeb, 1927), pigs (Duncan, Bowerman, Anderson, Heam, 8. 
Melampy, 1960), and cows (Hiltbank 8. Casida, 1956), its 
effects upon the quality of continuing ovarian function in 
humans, where it exists, has been the subject of much debate. 
Stone, Dickey, and Mickal (1975) examined the immediate 
effect of abdominal and vaginal hysterectomy on 
estradiol-17-beta (E2) and progesterone levels, noting a drop 
in circulating steroids on the second post operative day. 
They found that all those whose hysterectomy had been 
performed during the follicular phase of the cycle exhibited 
no significant variation in progesterone levels, while all 
those performed during the luteal phase exhibited a 
significant ~nd persistent decrease. Furthermore, the E2 
levels of both the follicular and luteal phase patients were 
significantly lower than the preoperative levels, although 
there was no change in LH and FSH levels. The control group, 
(women who had undergone a routine laparoscopy), exhibited no 
significant variation or changes in E2, progesterone, LH, or 
FSH levels other than those fluctuations observed during 
normal menstrual cycles, thereby eliminating the possibility 
of the changes observed in the hysterectomy patients being a 
function of surgical technique and/or the anaesthetic 
employed. 
results. 
However, similar studies have yielded contradictory 
Nei ther Doyle, Barclay, Duncan, and Kirton (1971), 
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nor Beling, Marcus, and Markham (19713) found hysterectomy 
performed during the early luteal phase prolonged the 
functioning of the corpus luteum, while Andreoli (1965) noted 
that it was not effected by hysterectomy performed on the 
twentyfourth day of the cycle (i. e. during the late luteal 
phase), but was prolonged when performed on the seventeenth to 
the nineteenth day of the cycle (i. e. during the mid luteal 
phase) . It is possible then that the timing of the operation 
is important for hysterectomy to have an immediate effect on 
corpus luteum function, and that that effect is only apparent 
during the cycle in which the operation is performed, since 
normal cyclical ovarian function was subsequently observed by 
these researchers. (Stone et al., 1975; Doyle et al., 1976; 
Beli ng et al., 19713; Andreoli 1965). 
Backstrom, Smith, Lothian, and Baird (1985) compared the 
post hysterectomy steroid levels in women with and without PMS 
(who acted as controls) noting that follicular development and 
ovulation resumed less quickly in the PMS women. Furthermore, 
their FSH levels were significantly lower than those of the 
controls in the late follicular phase, although there was no 
difference in estrogen levels during this phase. However, 
Backstrom et al. (1985) did not carry this study on beyond the 
first postoperative cycle._ The permanency of such differences 
between the PMS group and controls then, cannot be 
ascertained. Similarly, it can only be inferred from this 
study that follicular. development and ovulation occurred more 
quickly in the non-PMS control group, although no mention is 
made of whether this was significntly different in any way to 
follicular development either prior to their hysterectomy, or 
in normal women. Corson, Levinson, Batzer, and otis (1981) 
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found no statistical differences in E2 and progesterone values 
between hysterectomized women and normal controls (i. e. women 
who have not undergone hysterectomy, and who ovulate and 
menstruate regularly). Similarly, continuing ovarian function 
was demonstrated in 80% of the subjects of Ellsworth, Allen, 
and Nisker (1983), in 64% of the sample of de Neef and 
Hollenbeck (1966), while Kaiser, Geiger, and Kunzig (1979) 
also found evidence of normal ovulatory cycles in 70% of their 
hysterectomy subjects. A difference in the incidence of 
normal ovulatory cycles between women with one or two 
remaining ovaries has also been suggested and reported 
(Beavis, Brown, 8. Smith, 1969; Leverton, 1958), although de 
Neef and Hollenbeck (1966) failed to find any such 
di fferences. Beavis et al. did report however, that one 
remaining ovary may function less efficiently than two with 
increasing age. 
Furthermore, there is little evidence in the literature to 
suggest that hysterectomy with ovarian tissue remaining intact 
hastens the onset of menopause. Whitelaw (1958) found evidence 
of estrogenic activity in hysterectomized women (comparable to 
age-matched normal women) up to six years after hysterectomy 
had been performed, thereby suggesting that the ovaries may 
continue to function for a considerable amount of time after 
the operation. Leverton (1958) found evidence of ovarian 
function as long as seven years after hysterectomy, while 
Beavis et al. (1969) observed that 75% of their sample 
ovulated regularly with normal cycle lengths for between one 
and thirteen years after hysterectomy. Likewise, of the total 
sample hysterectomized women studied by Bancroft-Livingston 
(1954), 95% exhibited active vaginal smears (reflecting 
ovulation) less than three years after hysterectomy, and 60% 
continued to exhibit active smears more than five years after 
the operation. These figures were also found to be. comparable 
to a matched control group of normal women. Whitelaw also 
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noted that only 30% of his subjects over the age of fortyfive 
years with ovarian tissue intact exhibited menopausal 
symptoms, and that those subjects who did exhibit signs of 
decreased estrogenic activity were of an age when the onset of 
menopause was expected. Similarly, Bancroft-Livingston found 
that ovulation occurred less frequently in hysterectomized 
women with advancing age, but comparisons with age-matched 
normal women yielded no significant differences between the 
two groups. 
The literature then has, by and large, failed to reveal 
any long term effects of hysterectomy on the quality of the 
functioning of the remaining ovaries. The immediate effects 
on E2 and progesterone levels noted by Stone et al. (1975) 
appear to be temporary and confined to the operative cycle, 
with normal ovarian function resuming fairly quickly for most 
women and continuing until the expected time of menopause. 
3 - 4: METHODS OF DETECTI NG OV ARI AN F UNCTION. 
Methods of detecting ovarian function have included 
monitoring basal body temperature (BBT) for the post ovulation 
increase (Corson et al., 1981 j Kai ser et al., 1979; Whi telaw, 
1958), gonadotrophin and estrogen activity from vaginal smears 
(de Neef 8. Hollenbeck, 1966; Whi telaw, 1958), and menopausal 
symptomatology (de Neef 8. Hollenbeck, 1966; Whitelaw, 1958). 
The more accurate and frequently used indices of ovarian 
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activity however, are the measurement of plasma and urinary 
hormone levels (Backstrom et al., 1981; Beling et al., 19713; 
Beumont et al., 1975; Corson et al. I 1981; Doyle et al., 1976; 
Ellsworth et al., 1983; Kaiser et al., 1978, 1979; Metcalf, 
Evans &. Mackenzie, 1984; stone et al., 1975). Since regular 
venepuncture is both painful and distressing and twelve hour 
urine samples inconvenient, Metcalf (1973) demonstrated that 
the measurement of the pregnanediol: creatinine ratio in small 
samples of urine provided the clinician with the same 
information about ovarian activity as did the individual 
measurement of changes in other plasma and urinary hormone 
levels. Thus, less frequent samples are adequate to assess 
ovarian function, making the participation in longitudinal 
menstrual research less demanding. It must be noted however, 
that these assessments of ovarian activity only indicate that 
ovulation may have occurred. For absolute proof of ovulation, 
pregnancy or the removal of the mature oocyte must first 
oc c ur. 
The precise day of ovulation, or the.expected day of 
menstruation have not been sp~cifically addressed in the 
literature assessing ovarian activity after hysterectomy, 
thereby implying that they are not neccessary to such 
assessment. Yet while this_may be so, the accurate prediction 
of cycle phase (including the expected day of menstruation) is 
crucial to long term research on PMS after hysterectomy. It 
is extrtemely important to be able to distinguish clearly and 
accurately between the phases of the menstrual cycle in order 
for the cyclicity of the physical and affective symptoms of 
PHS to be established in the absence of menstrual markers. 
However, although Backstrom et al., 1981, and Beumont et al., 
44 
1975 attempt" to identify the day of ovulation, neither 
adequately address these issues. Both derived the cycle 
phases from their predictions of the day of ovulation, and the 
days of the studies were numbered using the day that 
hysterectomy was performed as the reference point. Beumont et 
al. predicted ovulation as occurring on the day LH levels 
peaked, whereas Backstrom et a!. predicted it occurred on the 
day of the LH surge also, or on the day between the estrogen 
peak and the rise in pregnanediol. Backstrom et a1. used 
pregnanediol levels as reference points for the end of the 
luteal phase, although no specific attention was paid by 
either Backstrom et a1. or Beumont et a1. to specifying the 
expected day of menstruation. Their methods of predicting the 
phases of the cycle could therefore be subject to considerable 
error. Given that samples were collected twice weekly by 
Backstrom et a1. and three times a week by Beumontet a1., the 
days of LH, FSH, estrogen, and progesterone fluctuations may 
have occurred in between these collections. Predictions of the 
day of ovulation and the end of the luteal phase need only be 
slightly inaccurate for the corresponding assessment of tne 
cyclicity of the premenstrual symptoms to also become 
inaccurate. 
It seems then, that this area of premenstrual research, 
like others, is not without its problems, and as yet, there is 
no clear evidence supporting the findings of either Beumont et 
a!. (1975) or Backstrom et a!. (1981). 
SECTION TWO: THE STUDY. 
CHAPTER FOUR: METHODOLOGY. 
4-1: AIMS. 
In the light of the contradictory findings of Beaumont et 
al. (1975) and Backstrom et al. (1981> reviewed here in 
Section One, chapter 3-2, this experiment aimed to 
retrospectively recruit a sample of women, who having 
undergone hysterectomy and having at least one ovary intact, 
believed they still continued to experience premenstrual 
symptoms. The purpose of this was to prospectively collect 
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mood, physical symptom, and ovarian data from these women over 
a period sufficient in length to enable the use of spectral 
analysis, a statistical technique of particular relevance in 
the context of PMS research, and the assessment of ovarian 
function. 
The specific aim of this study was to firstly establish 
the existence of ovarian act{vity in the subjects, and to 
secondly assess whether they exhibited significantly cycling 
affective and/or somatic symptoms, and to then establish 
whether these cycling mood and physical symptoms were 
significantly related to the premenstrual phase of their 
menstrual cycle. 
4-2: INSTRUMENTS. 
Prospective daily recording of physical and affective symptoms 
beginning the day after the initial interview was to be 
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carried out by subjects each morning and was to reflect their 
status of the previous day. Upon its completion each daily 
diary was to then be sealed in an envelope. They were also 
required to collect a urine sample upon rising on Thursday and 
Monday morni ngs. The diaries and samples were collected on 
Monday, the Thursday urine sample being frozen until its 
collection. The necessary information and apparatui for the 
recording of the diaries and the collection of the urine 
samples was the.refore provided for each participant at the 
commencement of the study. Consent was also obtained from 
each subject regarding the future use of their data at this 
time. The study was to initially continue for 14 weeks, 
thereby covering at least three menstrual cycles. At the end 
of 14 weeks, each subject was assessed for such things as 
evidence of ovulation (as indicated by the analysis of the 
urine samples), commitment to the study, and available time on 
the part of the researcher. It was then decided on the basis 
of these factors whether each subject continued to participate 
in a second 14 week phase of the study. 
4-2-1: Daily Diary. 
The daily diary (Appendix 7) comprised of 4 sections: 
A: General information r_elating to name, date, and any 
medication being taken (including dose and time taken where 
applicable) . 
B: Eight bi-polar visual analogue scales (VAS) 100mm in 
length. The anchors were happy/unhappy, exhausted/full of 
energy, confident/not confident, very tense/calm and relaxed, 
friendly/hostile, very poor concentration/very good 
concentration, irritable/unflappable. In order to minimise 
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the probability of stereotypic responding, the direction of 
the poles was alternated for each subsequent scale. A score 
of 100 indicated a maximum negative mood, while the sum of the 
eight scales provided a daily mood score. Subjects were 
required to mark moods at their best, worst, and in general 
for each day. Clear instructions were given to place the 
'general' marker between the' best' and' worst' marker but not 
necessarily at mid-point. 
c: A checklist of six physical symptoms. They were breast 
tenderness, swelling, constipation, food cravings, headaches, 
and stomach cramps. Subjects responded no, mild, moderate, or 
severe, and were scored as 0, 1, 2, or 3 respectively. The 
sum of these ratings provided a daily physical symptom score. 
D: An opportunity to add further comments regarding the 
previous day if necessary. 
4-3: PROCEDURE. 
4-3-1: Selection Interviews. 
4-3-1-A: Ini tial Phone Check. 
With the aid of a phone-check form (Appendix 1) all subjects 
were screened by telephone to gain brief details of menstrual 
cycles, health, age, hysterectomy, and occurrence of their 
premenstrual symptoms pre and post hysterectomy. 
4-3-1-8: Initial Interview. 
From the phone check women were then selected to be 
interviewed prior to th~ commencement of the study in order to 
acquire more detailed information about menstrual cycle 
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history, current health status, dietary and sleep patterns, 
and stress level. Information about gynecological history was 
also required, including fertility and associated problems, 
and methods of contraception. Subjects were also required to 
provide details of their hysterectomy such as dates and 
reasons for it. They were also asked to relate details of 
their premenstrual symptoms prior to and post hysterectomy. 
This information was collected with the aid of the initial 
interview form. (Appendix 2). The women were asked to 
describe their symptoms in detail while a 10-item observer 
scale was used by the interviewer to rate them. (Appendix 3). 
They then completed two 36-item self-rating scales, one 
indicating their symptoms prior to hysterectomy, and the other 
their symptoms since hysterectomy (Appendix 4). These scales, 
designed by Steiner et al. (1980), retrospectively sample the 
somatic and affective symptoms of the syndrome. 
4-3-1-C: Mid-Study Interview. 
All subjects regardless of whether they were to continue 
with the second phase or not were interviewed at this point. 
With the aid of the Mid-Study Interview form (Appendix 5), 
subjects were questioned regarding any changes that may have 
occurred in their lifestyle (such as stress levels, 
occupation, health, diet etc.) during the time of the study. 
They were also asked to indicate their stress level during 
this period, and the severity of their premenstrual symptoms 
generally and during the previous cycle. This was carried out 
in order to get an overall picture of each woman's lifestyle 
during this period. 
Each subject was given the information about her ovarian 
49 
cycle length and incidence of ovulation that had been analysed 
from the urine samples gathered during the previous 14 weeks. 
For those subjects who continued on the study for a further 14 
weeks, the second phase proceeded as follows: At various 
intervals during this phase, each was given a calendar of the 
following month on which the predicted dates of ovulation and 
menstruation were marked. The premenstrual phase was also 
marked on these calendars. The purpose of this excercise was 
to assess whether this informaton about their ovulatory cycle 
would have any expectancy effects on the perception of their 
premenstrual symptoms. 
The collection of urine samples and completion of the 
daily diaries continued during this phase as before. 
4-3-1-D: End of Study Interview. 
At the end of the second phase of the study, each subject was 
again interviewed regarding changes in lifestyle during this 
phase. With the aid of the End of Study Interview form she 
was asked to give an indication of a) the severity of her 
premenstrual symptoms both du~ing the previous cycle, and 
during the second phase of the study in general, b) both her 
current stress level and her stress level in general during 
that phase of the study, c) her current stress level in 
comparison to her stress level at the mid-study point and at 
the beginning of the study. Subjects were then asked to 
report whether they had noticed any discrepancies between the 
marked dates on the calendars they were sent and whether they 
felt that this had altered their expectations about subsequent 
predicted ovulation dates. (Appendix 6). 
4-4: ANALYSES. 
4-4-1: Statistical Analysis. 
As the use of visual analysis and verbal description is of 
questionable validity (Sharpley 1981), one of a group of 
statistical techniques, namely time-series analysis, was used 
in this study. Spectral analysis, analysis in the frequency 
domain used here, has been used in the past in other contexts 
and disciplines, (Luce, 1970; Gottman, 1979; Jenkins & Watts, 
1968), and is of particular relevance in the context of PMS 
research. It has two main advantages over other analyses in 
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the time-series domain such as sample autocovariance function. 
Firstly interpretation is easier, and secondly the variance 
associated with various frequencies is of direct interest. 
(Hudson 1985) The Fourier Transform allows the variance at 
each frequency of any time-series to be calculated (at a 
discrete set of frequencies known as the overtone series) 
The spectral density function is the final product of these 
calculation& and is a measure of the variance or powe~_at each 
of the frequencies of the overtone series. 
When a bivariate case is involved as with PMS research, 
two additional statistics can be derived: 1, Coherence, the 
best linear relationship between the two series at each 
frequency, and 2, 'Phase, which is a description of the 
temporal relationship between the two series at each 
frequency. At a partioular frequency, if the spectral density 
is low, and coherence is high, the linear relationship is 
likely to be trivial. Phase can only be interpreted if 
coherence reaches significance. since the variance of phase 
increases dramatically as coherence approaches zero. Further, 
the response time between the two series can be examined by 
inspecting the slope of the phase over the range of 
significant coherence. A negative slope indicates the two 
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series are out of phase, with the first slope leading, while a 
positive slope indicates the second series leads. (Gottman, 
1979) . 
4-4-2: Urinary Analysis. 
Pregnanediol (metabolized progesterone), in urine was 
measured as was creatinine, a progesterone waste product. 
Metcalf et al. (1984) found that pregnanediol excreted in a 24 
hour period was reflected in the ratio of pregnanediol to 
creatinine. The measurement of this ratio was therefore used 
as an index of ovulation. Ovulation was judged to have 
occurred if one urine sample yielded a pregnanediol: creatinine 
ratio of > or = 5 mmol, or if the sum of two consecutive 
samples' ratios were> or = 7 mmol. If a sample yielded a 
ratio of less than these limits, then it was considered to be 
a follicular phase sample. (Metcalf, 1979; Metcalf et al., 
1984; Metcalf & Sanders, 1981.) 
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CHAPTER FIVE: RESULTS. 
5-1: OVERVIEW. 
Thirteen Pakeha women were finally selected to take part 
in this study. Of those who requested to take part and were 
not selected, reasons given were age was outside the 25-45 
year range, poor health, types of medication being used (such 
as hormonal preparations), and the presence of symptoms such 
as hot flushes that were indicative of the onset of manopause. 
Similarly, women with current psychiatric problems or 
undergoing traumatic life experiences were also excluded from 
this study. Those selected had undergone hysterectomy and 
maintained they still experienced PMS. All completed the 
first phase of the study, and four went on to complete the 
second phase. Of the nine who did not continue into the 
second phase, five did so due to lack of time on the 
experimenter's part, one was about to move out of the city, 
and three were not accepted due to concerns about their 
commitment to the study, and their stress levels. 
The age of these women at the time of the study ranged 
from 30-42 years (mean, 37.2 years; SD, 3.4). The elapsed 
time between hysterectomy and the commencement of the study 
ranged from 4 months to 6 years, 7 months (mean, 2.8 years; 
SD,2.5). All thirteen women had had a vaginal hysterectomy 
and three had had ope ovary removed, while the remaining ten 
had retained both ovaries. All had had children. Six women 
had two children, six had three, and one woman had four 
children. Two were on medication for asthma, while another 
three took daily doses of vitamin B6 and efamol. Of this 
latter group, one woman agreed to discontinue this medication 
for the duration of the study, while the other two women 
taking it refused to stop. It was decided to accept them for 
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the study on the basis of research findings failing to support 
the theory that vitamin B6 and efamol effectively reduce 
premenstrual symptoms. (Stokes 8. Mendels, 1972). 
Eleven of the women reported they had menstruated 
regularly prior to hysterectomy, one reported she had never 
menstruated regularly, and the other reported she had 
menstruated regularly until she had had children. Her 
menstrual cycles had become irregular from then on. 
5-2: INDIVIDUAL SUBJECT PROFILES: Information given at the 
Initial Interview. 
Subject 1, aged 35 years, had had a vaginal hysterectomy 
four months previously to ameliorate excessive bleeding. Both 
ovaries remained intact. She began menstruating at the age of 
11, and reported that her cycle was regular, between 27 and 32 
days in length. F rom age 1 4- 2 1 s he was us i n g t he 
contraceptive pill to relieve dysmenhorrea. She has three 
children and used the rhythm method of contraception from the 
age of 21 until her hysterectomy. She was 1.57 metres (m) in 
height, and weighed 50.8 kilograms (kg). This 94% ideal body 
weight. (New Zealand Calorie Counter, 1987). 
She reported that she was in good health, although she was 
taking ventolin for asthma approximately once a week. She 
jogs for twenty minutes daily, plays tennis twice a week, and 
cycles regularly. She eats three meals a day, does not smoke, 
and consumes little alcohol. Her stress level she described 
as moderate, and she has about eight hours sleep a night. 
She claims she suffered from PMS for twelve years prior to 
hysterectomy. Symptoms began at ovulation and would cease on 
menstruation. Since hysterectomy, these symptoms have 
continued to occur regularly, lasting approximately seven 
days, but are not as severe as they were prior to 
hysterectomy. 
Subject 2, aged 40, had had a vaginal hysterectomy 3 
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years, 4 months previously at the age of 37. Hysterectomy was 
performed to ameliorate excessive bleeding, and one ovary, 
found to be enlarged, was removed. Menstruation began at the 
age of 13. This was fairly regular, with cycle length being 
30-33 days. After her third child, 14 years previously she 
ceased using contraception as her partner had a vasectomy. 
Weighing 57.2 kg, and and standing 1. 65m tall, she was 99% 
ideal body weight. She described her health as very good, in 
spite of taking ventolin for asthma on alternate days. She 
excercises frequently, jogging approximately 30 kilometres a 
week, eats three meals a day (mostly vegetarian), is a 
non-smoker, and drinks socially. She reported her stress 
level as being moderate, has a full time job, and sleeps well. 
She claimed she experienced PMS for ten years up until her 
hysterectomy. The symptoms, lasting a total of seven days, 
began five days prior to menstruation and continued for two 
days during menstruation. However, since hysterectomy, she 
claimed she was unaware of the occurrence of these symptoms. 
Subject 3 was 36 years old. She had a vaginal 
hysterectomy 6 years before at the age of 30 to correct a 
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hormonal imbalance, weight problems, and PMS. Neither of her 
ovaries were removed. Menarche was at the age of 12, and her 
cycles regular and of 28 days duration. Methods of 
contraception used over a six year period and in between 
pregnancies (and prior to hysterectomy) were the IUD, the 
contraceptive pill, and depo-provera. She reported her weight 
fluctuates between 60.7 kg and 66.5 kg, approximately 103% 
ideal body weight. She was 1.57 m tall. She reported she was 
in good health and not on any medication. She exercises 
occasionally, does not smoke, and eats regular meals. She 
drinks little, and sleeps about eight hours a night. 
She described her stress level as mild, and said she 
experienced PMS for ten years prior to hysterectomy. These 
symptoms lasted for 25 of the 28 days of her cycle. Since 
hysterectomy, these symptoms last up to ten days during most 
months, and thei r severi ty has decreased. 
Subject 4 was aged 38 and had had a vaginal hysterectomy 6 
years, 7 months before aged 32. This was due to excessive 
bleeding, and it was found that her uterus was enlarged and 
hardened. Both ovaries remained intact. Menstruation began 
when she was 13, her cycles were regular, and lasted 28 days. 
She had two children and used the oral contraceptive pill for 
eleven years until she had the hysterectomy. She weighed 60 
kg, 104% ideal body weight, and was 1. 65m tall. She reported 
she eats two meals a day, choosing to miss breakfast, smokes 
at least one packet of cigarettes a day, and is a moderate 
drinker. Her stress level she felt was moderate, and she 
sleeps well. She was attending a fitness programme twice a 
week. 
She has two children and reported she suffered from PMS 
since the birth of her second child four years prior to her 
hys t e re c t omy. Since then the symptoms have continued 
regularly and last a~proximately fourteen days. She reported 
she was taking 200 miligrams (mg) vitamin B6 and 3000 mg 
efamol daily to alleviate the symptoms, which she found to be 
effecti ve. She would not agree to cease taking this for the 
duration of the study. 
Subject 5 was 37 years old. She had a vaginal 
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hysterectomy 3 years, 11 months beforehand aged 34. She said 
that although she had had heavy periods, the main reason for 
the hysterectomy was because she suffered from PMS. Neither 
of her ovaries were removed. She began menstruating at the 
age of 12 years. Her cycles were regular and lasted 30 days. 
She had two children and conceived her second child with the 
aid of fertility drugs. She used the oral contraceptive pill 
and depo-provera until her partner had a vasectomy. She was 
1. 55m tall and weighed 62.5· kg, 118% ideal body weight. She 
reported that she has arthritIs in her arm and took brufen 
daily. She also has hip problems and cannot excercise 
regularly. She does not smoke, she drinks socially, and and 
eats regular meals. At time the study began she was calorie 
counting in order to lose weight. She rated her stress level 
as severe as her marriage had recently broken up, and she was 
feeling the pressure of copng with a family alone. Her health 
problems and premenstrual symptoms also added to this strain. 
She sleeps lightly and for about eight hours a night. 
She had suffered fromPMS for seven years prior to her 
hysterectomy, with the symptoms lastng ten days. She felt she 
still experienced these symptoms every 28-30 days, and they 
would last 8-10 days. 
Subject 6 was 41 years old and had had a vaginal 
57 
hysterectomy four months previously because of pelvic pain and 
excessive bleeding. One ovary was removed. Menarche was at 
the age of 11, and menstruation occurred regularly. She 
reported her cycle length was 35 days. She had two children, 
and except when pregnant, used the oral contraceptive pill 
over a ten year period. She ceased using contraception when 
her partner had a vasectomy seven years prior to her 
hysterectomy. She weighed 60 kg, 109% ideal body weight, and 
stood 1.60111 tall. She felt her health was good. She 'eats 
three meals a day, is a non smoker, and rarely consumes 
alcohol. She described her stress level as between mild and 
moderate and gets about 7 hours sleep a night. 
She reported she had experienced PMS regularly for ten to 
twelve days each cycle for seven years prior to hysterectomy. 
She felt she has continued to to experience these same 
symptoms of the same duration and severity since the 
hysterectomy. 
Subject 7, aged 40, had had a vaginal hysterectomy ten 
months previously at the age of 39 due to excessive bleeding. 
One ovary was removed. She began menstruating at the age of 
11, her cycles being_ regular and lasting about 28 days. She 
had two children, and used the oral contraceptive pill and 
depo-provera before having a tubal ligation, 11 years prior to 
hystel'ectomy. She weighed 59 kg, 104% ideal body weight, and 
was 1. 63m tall. She reported her health to be excellent. She 
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eats three meals a day, mostly natural health foods, is a non 
smoker, a non drinker, and cycles daily. She described her 
stress level as mild and said she was a restless sleeper. 
She had experienced PMS for about four years prior to 
hysterectomy, with symptoms lasting about twelve days. Since 
the hysterectomy she felt she still experienced these symptoms 
monthly although they were milder and of three to four days 
duration. 
Subject 8 at the time of the study was 42 years old. She 
had a vaginal hysterectomy at the age of 36, 6 years, 6 months 
previously due to excessive bleeding. Neither of her ovaries 
were removed. Menstruation began when she was 13 years old. 
Her cycles were irregular, fluctuating between 10 and 24 days 
in length. Methods of contraception were the contraceptive 
pill and the IUD. She had difficulty in conceiving her third 
child and had a tubal ligation after that birth. She was 
1. 73m tall and weighed 67 kg, 107% ideal body weight. She 
described her health as good. She ~_ats regular meals, does 
not smoke, and drinks socially. She does not excercise 
regularly. She rated her stress level as moderate, and 
generally sleeps well for about seven hours a night. 
She reported she had experienced PMS for three to four 
days each cycle for five years prior to hysterectomy. She 
felt that since the hysterectomy these symptoms had continued 
in the same pattern as they had before. She was currently 
taking 200mg vitamin B6 and 3000mg efamol daily to alleviate 
these symptoms. She was not willing to cease doing this for 
the duration of the study. 
Subject 9, aged 35 at the time of the study, had a vaginal 
hysterectomy thirteen months previously. She reported that 
the hysterectomy was performed for a number of reasons. She 
had had an embedded IUD, thrush infections, heavy bleeding, 
and a prolapse. Both ovaries remained intact. Menarche was 
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at the age of 12. Her cycles were not regular until after the 
birth of her last child and they fluctuated between 14 and 35 
days in length. She used the contraceptive pill and the IUD 
as methods of contraception in between four pregnancies, and 
up until she had the hysterectomy. She was 1. 63m tall, and 
weighed 88.9 kg, 157% ideal body ~eight. She described 
herself as being very healthy, and feeling especially well 
since the hysterectomy. She eats regular meals, and tries to 
eat healthily. She consumes a moderate amount of alcohol, and 
gave up smoking just prior to the hysterectomy. She felt her 
stress level to be severe at the time as she and her family 
had recently returned to New Zealand from overseas. She felt 
she had been under a great deal of stress because of this. 
She reported she had always. had PMS before her 
hysterectomy with the symptom~ lasting for seven days. Since 
then these symptoms had continued regularly, lasting five to 
nine days each month. She took vitamin B6 and efamol to 
alleviate the symptoms, but agreed to discontinue this for the 
duration of the study. 
Subject 10, aged 38, had a vaginal hysterectomy 5 years, 8 
months previously at the age of 33. Neither of her ovaries 
were removed, and hyst~rectomy was performed due to excessive 
bleeding. Menstruation began at the age of 13, and her cycles 
were regular and of 21-28 days duration. She had had three 
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children and one miscarriage, and had used the contraceptive 
pi 11. She described her health as good, although she did have 
an occasional problem with fluid retention. She took 
modiuretic tablets for 2-3 days every second month to 
alleviate this. She said she eats regular meals, does not 
smoke, and has the occasional drink. She was 1. 57m tall, and 
weighed 47.5 kg, 87% ideal body weight. 
She felt her stress level was mild and and reported she 
had experienced PHS for six years prior to hysterectomy, with 
the sympyoms lasting 3-4 days. For two years after the 
hysterectomy these symptoms ceased. They then began to recur, 
and she reported she had experienced them for 2-3 days each 
month for the past three years. 
Subject 11, aged 33, had a vaginal hysterectomy 8 months 
prior to the study. The reason for this was excessive 
bleeding, and clotting. Neither of her ovaries were removed. 
She began menstruating when she was 13 years old. Her cycles 
were regular, and of 28 days duration. She had two children, 
one miscarriage, and a termination following an ectopic 
pregnancy. She had used the contraceptive pill for 
contraception. She reported her health was generally good, 
although she had had an operation on her wrist six months 
pre vi ous 1 y. She eats re gul ar meal s, exe rc i ses regularly, 
consumes little alcohol, and smokes approximately one packet 
of cigarettes a fortnight. She rated her stress level as 
moderate, and sleeps about nine hours a night. She was 1. 55m 
tall, and weighed 60.7 kg, 115% ideal body weight. 
Prior to the hysterectomy she experienced PHS every month 
which would last about seven days. Since then she felt this 
pattern had continued unchanged. 
Subject 12 was 30 years old and had had a vaginal 
hysterectomy 9 months previously due to acute pain, heavy 
bleeding and a prolapse. Both ovaries had remained intact. 
Menarche was at age 11, and her cycles were regular until she 
had children. the length then fluctuated between 21 and 30 
days. She had three children and used an IUD until she had a 
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tubal ligation five years prior to hysterectomy. She reported 
she was on ventolin for asthma, and has cortisone injections 
every six weeks in summer. 
kg, 123% ideal body weight. 
She was 1. 65m tall, and weighed 61 
She reported she has two meals a 
day, skipping breakfast, does not smoke, and drinks socially. 
She rated her stress level as moderate 
She felt she had suffered from PMS since she began 
menstruating. The symptoms would last between seven and ten 
days, and became more severe as she got older. Since her 
hysterectomy she reports these symptoms have continued in the 
same pattern as before but they are not as severe. She also 
reported that following the hysterectomy she experienced 
severe fluid retention and h6t flushes. It was thought that 
her ovaries had ceased to function. However these symptoms 
subsided quickly and had not recurred at the time of the 
study. 
Subject 13, aged 39, had had a vaginal hysterectomy 12 
months previously due to excessive bleeding. Neither of her 
ovareis were removed. She began menstruating at the age of 
10, with cycle length being 21 days. She used depo-provera as 
a method of contraception, and had two children. Following 
the birth of her second child her cycles became extremely 
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irregular. She described her health as being good, and said 
she eats regular meals, is a non smoker, and consumes little 
alcohol. She was 1. 68m tall, and weighed 76 kg, 124% ideal 
body weight. 
She rated her stress level as mild and claimed she 
experienced PMS for five years up until the hysterectomy. The 
symptoms would last fourteen days. Since the hysterectomy she 
said the pattern of the symptoms have remained unchanged. 
5-3: SPECTRAL ANALYSIS. 
Results from all subjects will be presented along with 
spectral density analysis (Table 5-1). The spectral analysis 
graphs are presented in Appendices 8 and 9. 
Table 5-1: Spectral Density Analysis. 
SUBJ ECTS (S), SEGMENT (SEG), NUMBER OF 
DATA POINTS (T), BANDWIDTH (BW), MEAN 
SPECTRAL DENSITY AND SIGNIFICANT CYCLICITY 
(MSD), SUM OF PEAK (SP), PERIOD OF 
RANGE PEAK (PRP), DEGREES OF FREEDOM (DF), 
CHI SQUARED (CHI SQ), SI GNI FI CANCE (SI G) , 
MOOD/SPECTRAL DENSITY (MOOD/S), PHYSICAL 
SYMPTOMS/SPECTRAL DENSITY (PHYS/S), PREGNANEDIOL 
(P' DIOL). 
S SEG T BW MSD SP PRP DF CHI SIG 
26 SQ 
MOOD/S 1 61 0.0556 17150 510300 20-54 1 8 1 08 001 
26 
P' 01 OL 1 61 0.0556 3999 255020 18 -81 1 8 144 001 
29 
PHYS/S 1 61 0.0309 2. 1 0 64. 2 20-54 HI 60 001 
1 3 
19. 9 9.5-13.5 1 0 60 01 
27 
63 
pI DIOL 161 0. 0309 4008 244039 18-54 HI 70 · 001 
13 
39560 10-16 10 70 .05 
32. 5 
2 MOOD/S 195 e. 13462 3178 111276 16-& 18 234 .13131 
1 1 
39544 9.3-14 18 144 .13131 
1 1 
63779 7.2-14 18 252 · 131 
28 
P' DIOL 195 e. 13462 1135 98465 18-196 18 198 .13131 
81377 18 126 NS 
32. 5 
PHYS/S 195 e. 13462 e. 51 6. 99 21.6-97 18 144 .0135 
1 5 
6. 34 12-18 18 126 .13135 
6. 5 
1 13.26 5-8 18 2713· .1305 
29. 7 
3 MOOD/S 11 8 0. 04213 13055 4764913 17-60 10 613 · 001 
79261 10 120 NS 
29. 7 
P' DIOL 11 8 e. 13420 159. 2 7592 13-119 10 90 · 001 
863.01 113 90 .001 
29. 7 
PHYS/S 11 8 0. 13420 4. 86 146.07 17-119 113 70 .001 
13. 3 
42. 1 9-145 113 60 .05 
29. 7 
4 MOOD/S 119 0.0588 3342 47547 17-119 14 98 · 1301 
13. 3 
39351 6.6-14.8 1 4 154 NS 
29. 7 
P' DIOL 11 9 0.0588 1738 921311 13-119 10 713 · 13131 
39. 7 
PHYS/S 11 9 13.13420 4. 83 142. 9 19.8-119 113 613 · 13131 
29. 7 
P'DIOL 119 0. 0420 1681 841354 15-59 113 70 .1301 
94 
5 MOOD/S 188 0. 0263 5893 292136 10.5-109 10 190 · 001 
27 
P' DIOL 188 9920 5883213 21-37.8 10 50 · 0131 
27 
PHYS/S 188 13.0476 0. 53 24. 33 17-108 18 198 · 1301 
27 
P' DIOL 188 0.13476 9897 17-47 10 50 · 1301 
32. 5 
6 MOOD/S 195 e. 0256 13937 667570 18-65 10 913 · 001 
1 5 
111143 1 3 -18 10 50 
· 13 1 
1 5 
124970 1 3 -18 10 70 NS 
32. 5 
P'DIOL 195 0.0256 5298 360698 21.6-65 1 0 70 · 1301 
16 
98160 1 3 - 21 10 70 · 001 
32. 5 
PHYS/S 195 0.0462 5. 82 359.53 19-97 18 216 · 013 1 
32. 5 
P'DIOL 195 0.0462 5297 392120 19-97 18 162 · 001 
64 
21. 6 
7 MOOD/S 212 13.13231 251 51 811311313 15-43 113 11313 · 13131 
134787 NS 
24 
P'DIOL 212 13.13231 911.32 691136 18-42 113 11313 · 13131 
24 
PHYS/S 212 13.13417 1 . 31 66. 1 15-1138 18 252 · 13131 
27 
P'DIOL 212 13.13417 9136. 38 .72844 18-1138 18 198 .13131 
313 
8 MOOD/S 91 e. 13549 813313 17111313 15-91 113 613 · 13131 
49579 113 513 NS 
91 
P' DIOL 91 e. 13549 868 25172 18 - 91 113 513 .13131 
PHYS/S 91 13.13549 1. 79 11 . 21 113 913 NS 
16 
9 MOOD/S 129 13.13385 51136 2131388 9-1313 113 1413 · 13131 
25276 113 513 NS 
32. 5 
P' DIOL 129 13.13385 1243 751353 12-1313 113 11313 · 13131 
43. 3 
PHYS/S 129 13.13385 2. 29 71 . 5 13-1313 HI 11313 · 13131 
8.6 
4121. 25 5.4-13 1121 15121 NS 
18 
1121 MOOD/S 1138 13.121463 5983 61321 14-36 113 513 · 13131 
1 1 
68899 7.7-14 1121 7121 · 1313 1 
27 
P'DIOL 1138 13.13463 1243 43468 16-1138 1121 7121 · 13131 
18 
PHYS/S 1138 121.121463 2. 29 92. 37 7-108 10 16121 · 1211211 
22 
1 1 MOOD/S 11 0 0.0455 17541 329570 15-1113 10 70 · 0131 
12 
1969913 9-15 10 613 · 1301 
27. 4 
P'DIOL 1113 0.0455 532. 4 23684 15-11121 1121 • 7121 · 001 
27. 5 
PHYS/S 110 121.13455 6. 39 171 . 4 16-55 1121 100 · 131211 
12 
58. 8 9-16 10 6121 · 13 1 
47.26 913 NS 
95 
12 MOOD/S 95 e. 13526 11314 9791121 23-95 4 4121 · 13131 
1 4 
18133137 8-24 9 9121 · 13131 
24 
P'DIOL 95 e. 13526 1268 51378 14-95 7 713 · 131211 
31. 6 
PHYS/S 95 0.13526 9. 79 289.43 15-95 6 6121 · 13131 
32 
1 3 MOOD/S 96 13.121521 1721 5233121 12-96 1121 8121 · 1211211 
116331 1121 7121 NS 
P' 01 OL 96 121.121521 2712 5965.4 NS 
32 
PHYS/S 96 121.121521 4. 1 1 1 3121. 4 1121-96 1121 9121 NS 
Significance for coherence was established according to the 
methods suggested by Jenkins and Watts (1968). A critical 
value of 0.56 was established to ensure that there was no 
overlap between a coherence of zero and the 95% confidence 
interval around this critical level. Provided coherence 
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reached this critical value, and there were significant peaks 
within both of the spectral density functions, phase and slope 
of the phase graph could be interpreted. (Gottman, 1979; 
1981>. 
5-4: DATA SUMMARY. 
Subject 1. 
Results for subject 1 sho~s significant cyclicity for mood, 
physical symptoms and pregnanediol. However when calculating 
the relationship between mood and pregnanediol, and physical 
symptoms and pregnanediol the coherence values fail to reach 
significance on both counts. Thus in each case no phase is 
able to be interpreted and no relationship between mood and 
pregnanediol, and physical symptoms and pregnanediol 
establi shed. 
Subject 2. 
These results showed significant cyclicity for mood, physical 
symptoms and pregnanediol. Again significant coherence was 
not established for both the mood/pregnanediol and physical 
symptoms/pregnanediol relationships. 
no significant relationship exists. 
Subject 3. 
In each case therefore, 
Significant cyclicity for mood, physical symptoms, and 
pregnanediol was evident for subject 3. Coherence between the 
mood/pregnanediol data was significant. Interpretation of the 
phase relationship reveals a 5 day lag. However it was not 
possible to determine a mood or pregnanediol-lead slope. 
Coherence between physical symptoms and pregnanediol was also 
established, with a 6 day lag and a slope suggesting that 
pregnanediol leads. 
Subject 4. 
Mood, physical symptoms and pregnanediol cyclicity was 
si gni fi cant. Coherence failed to reach significance for mood 
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and pregnanediol. However, coherence of 0.52 for the physical 
symptoms/pregnanediol relationship just failed to reach 
significance at 0.56. If this was accepted then phase 
interpretation suggests that pregnanediol leads by 0.5 of a 
day. 
Subject 5. 
Evidence of significant cycling mood, physical symptoms, and 
pregnanediol was established for subject 5. No significant 
coherence was established for the mood/pregnanediol 
relationshi p. Thus, phase was uninterpretable. Coherence did 
reach significance for the physical symptoms/pregnanediol 
relationship however, with a pregnanediol-lead approximately a 
day and a half phase shift. 
Subj ect 6. 
Results here showed significant cyclicity for mood, physical 
symptoms, and pregnanediol. Significant coherence was 
established for both the mood/pregnanediol and the physical 
symptoms/pregnanediol relationships. In each case a 
pregnanediol-lead phase lag of approximately 4 days was 
evident. 
Subject 7. 
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Mood, physi cal s ympt oms, and pregnanedi 01 cyc 1 ed 
si gni fi cantly. Coherence was just significant for the 
mood/pregnanediol relationship. Phase interpretation revealed 
a mood-lead slope with a 2.5 day lag. Physical 
symptoms/pregnanediol coherence was also significant with a 
1-2 day phase lag. It is not clear however, whether physical 
symptoms or pregnanediol lead. 
Subj ect 8. 
For subject 8 evidence of significantly cycling mood and 
pregnanediol exist, although the cyclicity of pregnanediol 
seems questionable. There appears to be no real detectable 
cyclicity of physical symptoms. Despite this, coherence 
between mood and pregnanediol is significant. Phase 
interpretation reveals a 4 day lag although it is unclear 
whether mood or pregnanediol leads. 
Subject 9. 
Results for subject 9 reveal significant cyclicity for mood, 
physical symptoms, and pregnanediol. Coherence failed to 
reach significance for the relationship between both mood and 
pregnane di 01, and phys i cal s ympt oms and pregnanedi 01. No 
phase interpretation could therefore be calculated. 
Subject 1e. 
Significant cyclicity for mood, physical symptoms, and 
pregnanediol was established, with no significant coherence 
noted for either the mood/pregnanediol relationship or the 
physical symptoms/pregnanediol relationship. Phase was 
therefore uninterpretable. However it is of interest to note 
that mood and physical symptoms were found to be cycling 
together. 
Subject 11. 
Cyclicity for mood. physical symptoms, and pregnanediol were 
found to be significant. However, coherence was not 
significant for either mood and pregnanediol, or physical 
symptoms and pregnanediol, and phase was not able to be 
interpreted. 
Subject 12. 
Significantly cycling mood, physical symptoms, and 
pregnanediol was found in subject 12. There was no evidence 
of significant coherence for the mood/pregnanediol nor the 
physical symptoms/pregnanediol relationships. 
therefore uninterpretable. 
Subject 13. 
Phase was 
In subject 13 significant cyclicity was established for mood, 
and physical symptoms only. Significant cyclicity could not 
be detected for pregnanediol and it was therefore impossible 
to estimate coherence significance. 
5-5: SUMMARY. 
Of the thirteen subjects, all showed evidence of significant 
cyclicity of mood. All but one (subject 8) had significantly 
cycling physical symptoms, while pregnanediol cycled 
significantly for all but subject 13. 
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A total of six subjects showed evidence of significant 
coherence for either the mood/pregnanediol relationship or the 
physical symptoms/pregnanediol relationship. The coherence 
for subjects 3, 6, and 7 reached significance for both mood and 
pregnanediol, and physical symptoms and pregnanediol. 
Subjects 4 and 5 revealed significant coherence for the 
physical symptoms/pregnanediol relationship only, while 
subject 8 revealed a significant coherence only for the 
mood/pregnanediol relationship. With regard to phase 
interpretation, of these six subjects, a pregnanediol-lead 
slope could be detected for subjects 4, 5, and 6, with a 0.5, 
1.4, and 4 day lag respectively. Intrepretation of phase for 
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subject 7 revealed a mood-lead mood/pregnanediol relationship, 
with a 2.5 day lag. It was not possible to determine which 
variable lead the physical symptoms/pregnanediol relationship 
for this subject, although there was a lag of 1-2 days. It 
was also not possible to determine which variable lead for 
subjects 3, and 8. A lag of 5 days for mood and pregnanediol, 
and 6 days for physical symptoms and pregnanediol was 
estimated for subject 3, while a lag of 4 days was estimated 
for subject 8. 
CHAPTER SI X: DI SCUSSI ON. 
6-1: INTERPRETATION OF RESULTS. 
Spectral analysis was applied to prospectively collected 
mood, phys i cal symptoms, and pregnanedi 01 data in order to 
determine the significance of their relationship. Six of the 
thirteen subjects showed evidence of significantly cycling 
mood and/or physical symptoms that were significantly related 
to the premenstrual phase of their menstrual cycle. These 
findings appear to be consistent with those of Backstrom et 
al. (1981) who also found evidence of cyclical affective and 
somatic symptoms in the presence of cyclic ovarian function. 
Continuing ovarian function was found in all but one 
subject (13) thereby supporting the findings of Ellsworth et 
al. (1983), de Neef and Hollenbeck (1966), and Kaiser et al. 
(1979). Of these twelve subjects, subjects 2, 6, and 7 had 
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only one ovary. Two of these women (subjects 6, and 7) showed 
significant mood and physical symptom cyclicity which 
significantly correlated to the premenstrual phase of their 
cyc 1 e. Subject 13, who failed to demonstrate any evidence of 
ovarian function, had reported that she had had extremely 
irregular menstrual periods prior to her hysterectomy, thus 
casting doubt on the functioning of her ovaries even then. 
If PHS has an underlying hormonal substrate as is 
postulated in the biochemical etiological theories of the 
condition, then one could expect that in the six significant 
mood or physical symptoms/pregnanediol relationships found 
here, pregnanediol should be the leading variable. This is 
the case for three of these six subjects. For the remaining 
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three subjects it was not possible to determine which variable 
lead, although it is at least plausible that pregnanediol also 
leads in these cases. 
With regard to the pregnanediol analysis itself, it must 
be noted that pregnanediol (metabolized progesterone) values 
are simply markers of the phases of the menstrual cycle. 
These values must reach a critical value before it can be 
concluded that ovulation has occurred, and that the hormonal 
event~ of the menstrual cycle are progressing as usual towards 
menstruation, whether menstruation is physically possible or 
not. It therefore cannot be assumed that although 
pregnanediol is the leading variable in these cases, that this 
is the underlying hormonal substrate of the syndrome. It may 
well be that other hormonal events that occur during this 
phase of the cycle are the underlying substrates of PMS. 
The urinary analysis then merely measured the pregnanediol 
levels. It is therefore beyond the scope of this analysis to 
measure deficiencies or excesses of progesterone, or to 
examine hormonal imbalances or ratios as has been implicated 
in the etiology of PMS. Nor is it possible to relate this 
analysis to the various nutritional theories of the syndrome. 
It is therefore inappropriate for comment to be made regarding 
the biochemical etiological theories of PMS beyond saying that 
for at least some subjects (3, 4, 5, 6, 7, and 8) ovarian 
cyclicity is related to their symptoms. 
For the remaining seven subjects, their affective and 
somatic symptoms bore no significant relationship to their 
menstrual cycle whatsoever. Significant cyclicity of mood was 
established for all seven subjects, with average cycle 
lengths of 26, 32, 16, 18, 12-22, 14-95, and 32 days bei ng 
noted for subjects 1, 2, 9, 1 e, 11, 12, and 13 respecti vely. 
Significant cyclicity of physical symptoms was also 
established for all of these subjects, with averege cycle 
lengths of 29, 32, 8-43, 18, and 12-27 days respectively. It 
is possible that these cyclical moods and physical symptoms 
could be totally unrelated to or independant of PHS. It may 
well be that their occurrence is related to psychological 
personality traits or neurotic tendancies, such as was 
proposed by Rees (1953), and Coppen and Kessell (1963). 
However, further assessment of these subjects must be 
conducted before any such conclusions should be made. 
Similarly it seems that having been aware of their cycling 
affective and somatic symptoms, these women have assumed in 
the absence of menstrual markers that they have occurred 
during the premenstrual phase of their cycle. Thus 
attributional processes may well be implicated here. Each 
subject believed her symptoms occurred cyclically during the 
premenstrual phase of her premenstrual cycle prior to 
hysterectomy. When these symptoms recurred after 
hysterectomy, she continued to attribute their causation to 
the premenstrual phase of her cycle. This in turn leads one 
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to question whether these symptoms were actually significantly 
related to their menstrual cycles prior to hysterectomy. As 
it was only possible to obtain prospective PHS data from one 
of the subjects in this group prior to hysterectomy, no firm 
conclusions can be made regarding this. For subject 10 and 
13, their affective and somatic symptoms appear to be cycling 
together. It is therefore also possible that there may be a 
significant relationship between these two variables as has 
been found before (Hudson 1985). However, due to time 
restrictions on the researcher, it was not possible to 
investigate this. 
6 - 2: METHODOLOGI CAL CONSI DERATI ONS. 
Methodological considerations for this study are as follows: 
1: Subject Selection. 
It is clear that this study has employed a biased sample of 
subjects. This study was limited to women between the age of 
25 and 45, who had undergone hysterectomy, and had at least 
one ovary intact. This study focused specifically on 
evaluating the existence of PMS post hysterectomy. It has not 
sought to make any comparisons with or generalisations to the 
existence of PMS in the general population. 
2: Data Collection. 
A) The daily diary used in this study included 10 visual 
analogue scales and a six-item symptom checklist. The VAS was 
unmarked and the negative poles of the questions were 
alternated to minimise the impact of stereotypic responding. 
B) The mood descriptor words on the daily diary rating scales 
may have forced women to rate their moods under labels that 
may not have been meaningful to them. However validity data 
suggest that this is acceptable (Hudson, 1985). Similarly, 
the physical symptom checklist required them to subjectively 
rate their symptoms as mild, moderate, or severe. 
C) Subjects were required to mark moods at their best, worst, 
and in general for each particular day on the daily diary 
rating scale. Clear instructions regarding the placement of 
these markers were followed by all subjects and closely 
monitored by the researcher. In the final analysis the value 
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of the' general' point only was used due to lack of time on 
the researcher's part. 
research however. 
This data can be used in future 
D) Data for this study was collected prospectively each day 
and sealed in an envelope upon completion to prevent referral 
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to it at a later time. While it could be argued that this was 
still retrospective given that self report is retrospective, 
and each daily diary recorded the previous day's events. 
However, this is still likely to be a more accurate indication 
of data than that which is collected later in time. 
E) Data was collected over at least three cycles and was 
therefore (albeit barely) sufficient for spectral analysis to 
be employed. However it was very time consuming. 
3: Ovarian Function. 
Ovarian function was calculated from urinary pregnanediol 
levels. While the most accurate method of calculating this is 
from plasma analysis, urinary analysis is the next accurate 
and most convenient method (Metcalf 1973). The aim of this 
analysis was to calculate pregnanediol levels only. This 
study did not set out to test any of the etiological theories 
of PMS in relation to this. 
4: Expectancy Effects/ Health. 
A) This study attempted to exclude women who were on 
medication, were severely stressed, or who showed signs of 
poor physical and/or mental health. In this way attempts were 
made to minimise the effects these variables may have had on 
the collection of accurate premenstrual data. 
B) Traditional expectancy effects were non-existent since the 
subjects initially lacked knowledge of their cycle phase due 
to the absence of menstual markers. 
C) For obvious reasons this study was not beset with such 
problems as subjects taking oral contraceptives, or 
pregnancies as have beset other' normal-subject' PMS research. 
5: Retrospective Data. 
Pre hysterectomy data was collected retrospectively for all 
but two subjects. The implication for this study is that it 
may have included women whose somatic and affective symptoms 
may not have been significantly related to their menstrual 
cycles prior to their hysterectomy. This could explain why 
seven of the subjects failed to show evidence of cyclicity of 
mood or physical symptoms that was significantly ralated to 
the i r c yc 1 e. 
6 - 3: S UGGESTI ONS FOR FUTURE RESE ARCH. 
Suggestons for future research include: 
1) Analysis of the relationship between affective and somatic 
symptoms, irrespective of their relationship to the menstrual 
cycle which has not been able 'to be addressed in this study. 
2) A prospectively conducted longitudinal study of women 
throughout their menstrual life would be ideal. However it is 
accepted that this type of study would need initially to be 
conducted on an immense scale, and would be fraught with 
difficulties. A more practical study would be one which 
prospectively recorded the premenstrual data of women about to 
undergo hysterectomy in order to initially test for the 
existence of significant cyclicity of affective and somatic 
symptoms that are significantly related to their menstrual 
c ycl e. This would mean delaying the operation in order to 
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achieve this. Once hysterectomy has been performed, it may 
then be possible to not only establish whether these symptoms 
continue to occur, but it may also be possible to identify two 
distinct subgroups from this sample: One whose affective and 
somatic symptoms are significantly related to their cycle in 
the absence of menstrual markers, and one whose mood and 
physical symptoms do not have any significant relationship to 
their cycle. These women's symptoms may be operating on the 
basis of a psychological marker. Retrospective comparisons 
could then be made between these subgroups regarding such 
things as symptomatology, severity, onset and duration. 
Comparisons could also be made between pre and post 
hysterectom,y symptomatology. 
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APPENDIX 1 
NAME: 
INITIAL POONE CHOCK 
To identify worren 25 - 45y, rn:inus uterus, with at least 1 ovary, and in 
reasonable health. 
Age (if not on reply form) 
Hysterectany 
PMS Pre-op 
Post-op 
Health and medication 
Cmmitment 
Do you know anyone else? 
For worren meeting our needs: 
- How old are you? 
- When? 
- For what reason? 
- Were your ovaries removed? 
- How bad was your PMS? 
- How long did you have it? 
- When did it occur each month? 
- How bad is your PMS now? 
- How often do you notice it? 
- How long does it last? 
- State of health 
- Any medication? 
(give names and reasons) 
- Can you fill in a short form 
each day for 14 weeks and provide 
a urine sample x 2/week? 
- Can you forego the use of medication 
which might alter your moods 
during this time? 
- At the end of the 14 weeks we 
would tell you what your ovaries are 
doing and when you ovulate, and we 
would discuss with you what next to 
do in the PMS study. 
Make an appointment to interview (allow approximately 1 hour). 
Tine of Interview 
Date 
Place 
APPENDIX 2 
Pm1ENSTRUAL SYNDRCI1E INITIAL INTERVI.E.W 
Date ••................. 
Full name (with title) 
Address ...••.••......•.....••.......• ( horne) .•. ...... (work) 
Telephone No •.......••••.••.••.•.•••• ( day) •..•.••••••••••••••• ( evenings) 
Age .................................. Date of Birth ...................... . 
Date of Hysterectomy. 
Name of Surgeon .. 
Name of Hospital ........ . 
Reasons for hysterectomy .• 
Were any ovaries removed? ........... . 
Have you had any other gynaecological surgery (give details)? 
How have you felt since the operation? ................................. . 
Menstrual cycle history 
Haw old were you when your periods started? 
Did they occur regularly? 
How long were your cycles? average time 
shortest 
longest 
Did you have any period pains? 
Did you have mid-cycle pain 
Do you still have this pain?-
(or discomfort)? 
If you do, how often do you feel it? 
How heavy were your menstrual bleeds? 
How long did the bleeding persist? 
State of Health ........................................................ . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
APPENDIX 2 (contd ... ) 
Current drugs (rredicines) .•. 
Non-gynaecological Operations (with dates) •. 
Method of Cohtraception •• . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
If oral/injected contraceptives:-
( a) 
(b) 
duration of treatrrent .•• 
date on which it ceased. 
Reproductive History:-
Ages of children .•. 
Miscarriages 
Fertility problems •• 
Height 
Weight 
Diet: 
(a) daily rreal pattern (no. of neals/day) .••..••.•••...•.•..••••••.••....• 
(b) food dislikes ......... . 
(c) variability in food intake fran day to day ••. 
( d) alcohol intaJ<.e ..................................... " ................ . 
( e) SITlC)kin 9 l1ab its. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ............ . 
( f) hOllrs of sleep ...................................................... . 
Occupation: 
( a) nt.:IrIit>er of }?f3ople cared for .••.....•..•.•....•...................••...• 
(b) hours of paid ernployrrent ••••••.•••••.•••...••..•.••••••••••.•••• 
(c) extent of other t.iJre consuming occupations ... 
(d) t.iJre s}?f3nt on sporting activities/week (e.g. 
Recent changes: 
jogging etc) •••.••••••••• 
( a) in residence. . ............................................. . 
( b) in occupation •...•.•••.••••.•.•••.••.•..•...••.•..•..••••.•••••••••••• 
APPENDIX 2 (contd ... ) 
( c) people lived with 
( d) close friends ........................ . 
(e) responsibilities ...•.................. 
stress Level:-
Premenstrual Tension 
MILD IDDERATE SEVERE 
Duration (years) .................•.........................•............• 
Duration each month before hysterectomy? 
Do . you get PMr now? .....•.....•................•........•..•.....•.....• 
If you do, how often do you get it? .............•.•.....•.....•.•.•••... 
and how long does it last? 
****************************** 
Specimens and records collected on 
Arrangerrents for specimen 
Appointrrent dates 
collection 
Authority given to obtain surgical information ..•..................•..•. 
APPENDIX 2 (contd ... ) 
Enquiries to:-
Dr Glen Metcalf 
Princess Margaret Hospital 
Phone: 39-169 Ext 847 
EVERY MJRNING: 
Departrrent of Endocrinology 
or Ms Lynette Bamber 
Phone 884-322 
or Mrs Di Skidmore 
Phone 792-890/495 work 
516-217 home 
Before starting the day's activities, complete the 
questionnaire and seal it into the envelope provided; 
label the envelope with the date. 
(Ii ~ & 'IHURSDAYS: 
a. On waking, collect a urine specirren in the container 
provided. 
b. Write your narre and the date on the specirren container 
and the date on the urine form. 
Put specirren and form together in the plastic bag, 
and place them in your freezer until they are collected. 
Put the week's envelopes (containing the questionnaires) 
plus the 2 plastic bags (containing specirren and pathology form) 
in a brown paper bag; deliver the bag before 8.30 a.m. to: 
If you have any problems do not hesitate to phone. 
APPENDIX 3 STEINER OBSERVER RATING SCALE 
RAT~ OCALE FOR PREMENSTRUAL TENSla-l SYNDlU1E 
Narre: Rater: _______________ Date: __________ _ 
------------------------------
Circle the most appropriate score for each item: 
1. Irritability-Hostility (0-4) 
(Irritable, hostile, negative 
attitude, angry, short-fused, 
yelling & screaming at others) 
o. Not irritable. 
1. Doubtful, trivial. Not 
reported without direct 
questioning. 
2. 
3. 
Mild, Occasional outbursts 
of anger and hostile 
behaviour. Spontaneously 
reported. 
Moderate, Irritable behaviour 
evident. Frequent outbursts. 
4 . Severe. Affects most inter-
actions between patient and 
significant others. 
2. Tension (0-4) 
4. Dysphoria (0-4) 
5. 
(Dysphoric mood, distinguish fran 
depression) 
O. Not dysphoric 
1. Somewhat blue, sad. Elicited 
only on direct questioning. 
2. Mild dysphoric and labile mood, 
spontaneously reported. 
3. Marked spontaneous emotional 
lability: occasional crying, 
feelings of loneliness. 
4. Severe, obvious and persistent. 
Motor Co-ordination (0-4) 
(Clumsy, prone to accidents, lowered 
motor co-ordination) 
O. No disturbance. 
1. Doubtful, trivial. 
(Tense, restless, jittery,upset, 
high-strung, unable to relax) 
. 2. Mild clumsiness, feels awkward. 
3. Moderate. Frequent "accidents". 
4 . Severe impainrent in motor co-
ordination, e.g. unable to write 
properly, sew, or unable to 
drive. 
3. 
o. 
1. 
2. 
3. 
Not tense. 
Doubtful, trivial. 
Mild. Reports occasional 
tension. 
Moderate. Tense, jittery, 
unable to relax. Restless 
behaviour evident. 
4. Severe. Constantly tense 
and upset. 
Efficiency (0-4) 
(Decresed efficiencY, 
fatigued) 
o . No disturbance. 
1. Doubtful, trivial. 
easily 
2. Mild. Somewhat reduced 
efficiency. 
3. Moderate. Easily fatigued, 
gets much less done than 
usual. 
4. Severe. Fatigue causes serious 
interference with functioning. 
6 .. Mental - cognitive functioning (0-4) 
(Forgetful, poor concentration, 
distractable, confused, lowered 
judgement) 
O. No disturbance. 
1. Doubtful, trivial. 
2 • Mild. Slight forgetfulness 
and distractability. 
3. Moderate. Performance illlpaired 
by poor concentration, cognitive 
disorganisation, forgetfulness, 
etc. 
4 • Severe. Marked deterioration in 
cognitive capacity, poor 
judgement, leading to 
regrettable decision. 
APPENDIX 3 (contd •... ) 
7. Eating habits (0-2) 
o . No change. 
1. Mild increase in food 
intake, eating at odd 
irregular hours, mostly 
snacks and sweets. 
2. Obvious, marked increase. 
Uncontrollable cravings 
for sweets, chocolate, etc. 
8. Sexual drive and activity (0-2) 
o . No change. 
-2-
1. Mild but consistent increase 
or decrease in sexual 
drive, desire, libido. 
2 . Marked change in sexual 
drive with definite change 
in sexual behaviour. 
9. Physical sympt9ffiS (0-4) 
(Painful or tender breasts; 
swelling of abdorren, breasts, 
ankles, or fingers; water 
retention; weight gain; 
headaches, low-back pain etc.) 
o . No physical symptoms. 
1. Doubtful or trivial. 
2 . Mild. Sorre symptoms, 
increased awareness of 
bodily changes. 
3 . Moderate. Obvious changes 
and complaints. 
4 • Severe. Physical symptoms 
are incapacitating. Pain 
and discomfort. Marked 
water retention and 
edema.. W~ight gain rrore 
than 5 lbs. 
10. Social impairment (0-4), 
Avoidance of social activities 
and interactions with family, 
at horre, at work, at school, 
etc. ) 
O. No social impairrrent. 
1. Doubtful, trivial. 
2. Mild avoidance of social 
activity. 
3. Moderate but obvious 
impairment of social 
activity, ma.inly notice-
able at horre and with 
family. 
4 . Severe. Marked impairment 
of most social interactions 
including at work or 
school. Withdrawal, 
isolation. 
Total score .•••••..•...•••• 
APPENDIX 4 STEINER SELF RATING SCALE 
SELF RATING OCALE FOR PREMENSTRUN..TENSIOO SYNDID1E 
Narro: .........................•............ Date: ........................ . 
Instructions: The following questions are concerned with the way you feel or act 
tooay (or the way you felt or acted during the 'Week) . 
Please answer ALL questions by circling YES OR 00 as indicated. 
1. Do you find yourself avoiding some of your social corrmitments YES NO 
2. Have you gained 5 or more pounds during the past week? YES NO 
3. Is your co-ordination so poor that you are unable to use kitchen 
utensils, garden tools or unable to drive? YES NO 
4. Do you feel more angry than usual? YES NO 
5. Do you avoid family activities and prefer to be left alone? YES NO 
6. Do you doubt your judgerrent or feel that you are prone to hasty 
decisions? YES NO 
7. Do you feel more irritable than usual? YES NO 
8. Is you efficiency diminished? YES NO 
9. Do you feel tense and restless? YES NO 
10. Do you feel a marked change in your sexual drive or desire during 
the last week. (If YES, is it increased or decreased? YES NO 
11. Are your present physical symptans causing so much pain and dis-
comfort that you are unable to function? YES NO 
12. Have you recently cancelled previously scheduled social activities? YES NO 
13. Do you feel as if you were unable to relax at all? YES NO 
14. Do you feel confused? YES NO 
15. Do you suffer from painful or tender breasts? 
16. Do you have an increased desire for specific kinds of food ( e. g. 
cravings for s;V'eets, chocolate, etc.)? YES NO 
17. Do you scream/yell at family members (friends, colleagues) more than 
usual? Are you "short-fused"? YES NO 
18. Do you feel sad, gloomy, and hopeless most of the time? YES NO 
19. Do you feel like crying? YES NO 
20. Do you have difficulty completing your daily household/job routine? YES NO 
21. Was there a marked change in your sexual drive with definite change 
in your sexual behaviour during the last ,~ek? YES NO 
22. Do you find yourself being more forgetful than usual or unable to 
concentrate? YES NO 
23. Do you happen to have more "accidents" "lith your daily housework/job 
(cut fingers, break dishes, etc)? YES NO 
24. Have you noticed significaT1t swelling of your breasts and/or ankles 
and/or bloating of your abdomen? YES NO 
25. Does your mood change suddenly without obvious reason? YES NO 
26. Are you easily distracted? YES NO 
27. Do you think that your restless behaviour is not iceable by others? YES NO 
28. Are you clumsier than usual? YES NO 
29. Are you obviously negative and hostile towards other people? YES NO 
30. Are you so fatigued that it interferes with your usual level of 
functioning? YES NO 
31. Do you tend to eat more than usual or at ood irregular hours (sweets, 
snacks, etc.) YES NO 
32. Do you become more easily fatigued than usual? YES NO 
33. Is your handwriting different (less neat than usual)? YES NO 
34. Do you feel jittery or upset? YES NO 
35. Do you feel sad or blue? YES NO 
36. Have you stopped calling or visiting sorre of your bef.,t friends? YES NO 
BelO\l are tvo stater.ents concerning premenstrual tension s~mdrO!1'e. Please put a 
cross closest to the position you consider best describes your symptoms. 
1. How severe vlere your Pt-f.l' symptoms this last month? 
absent very severe 
-----------------------------------------------------
2. Hml severe "''ere your PMT symptoms over the past six months? 
APPENDIX 5 
PREMENSTRUAL SYND~: MID-SlUDY I.Nl'ERVIE.W 
Date ........................... . 
Full Narre:... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Interviewer: .•.••••.........•.•..•..•.•.......•.... 
(The interviewer should examine the information given at the first 
interview, the written comments on the daily diaries and the pregnanediol 
cyclicity before going to the interview). 
The Study so far 
How have you found the stilly?. 
Questions 
Since the stilly began, have you noticed any changes in the following (and 
if you have, please describe them):-
1. YOtlr diet ............................................................. . 
2. Smoking habits ..••. 
3. Alcohol intake .•• 
4. Hours of sleep ... 
5. Daily Activities •••••••.•••. 
6 • Number of people cared for •••••••••••...••••••..•••...•..•••••••.•••••• 
7. Job ••.••••••..•.••••.•..•••.• 
8. other tirre consuming c>c::cupa t ions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
9. Residence •••.•.....•. 
10. People lived with. 
11. Close friends ......................................................... . 
12. Responsibilities ••• 
13. Level of stress •••••••• 
14. Your PMI' •..•.••..•...•... 
15 . (;eneral Health ...........•............................................. 
16. Anything else •.......•..•.•...••..••••..••••..•.•...•.•••••••..••.•.••. 
APPENDIX 5 (contd ... ) 
Would you say your general level of stress during the study was:-
MILD MJDERATE OR SEVERE? 
Results 
You ovulated ............ tines during the study and are likely to do so 
again in about ....... days. The length of your ovarian cycle appears to 
be about ....... days. 
Continuation of study 
Calendar 
Are you willing to continue? ........ . 
Urine Pack. 
Specinens 
Specinens and records to be collected from 
by each 
Below are two questions concerning the prerrenstrual tension syndrare. Please 
put a cross closest to the position best describing your symptoms. 
1. How severe was your PMI' this last rronth? 
absent very severe 
2. How severe was your PMI' in general, during the last 3 months? 
absent very severe 
APPENDIX 6 
PREMENSTRUAL SYNDRa1E - END OF SIUDY INl'ERVIEW 
Date .•••....•...•.....•..•. 
full Narro: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Interviewer: .......•........••..•...•.....•...•... 
(The interviewer should examine the inforrna.tion given at the first inter-
view, the written carrrents on the daily diaries and the pregnanediol cyclicity 
before going to the interview). 
The study so far 
How have you found the study?. 
Questions 
Since the study began, have you noticed any changes in the following (and 
if you have, please describe them):-
1. Your diet .••..•.••••••.• -........................................... . 
2. Srroking habits •. 
Alcohol intake •. 
4. Hours of sleep .••• 
5. Daily activities ...•••.•.••. 
6. Number of people cared for. 
7. Job ................................. ' ............................... . 
8. other time consuming occupations. . . . . . . . . . ............. ~ ........... . 
9. Residence •••••.•••••• 
10. People lived with. 
11. Close friends ...................................................... . 
12. Responsibilities .................................................... . 
13. Level of stress ..................................................... . 
14. Your P.Mr ....•••...•..••••••••••••..••.•••.••••.....••••••.•••.••••••• 
15. General Health •.•.•••••.••..•• . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
16. .Anytlling else ....................................................... . 
APPENDIX 6 (contd •... ) 
1. On a scale of 0 - 10, how would you rate your premenstrual symptoms: 
(a) during the last rronth? 
(b) during the last 3 rronths? 
2. How would you rate your general level of stress during the last 3 
-rronths? 
mild moderate severe 
3. How would you rate your stress level now? 
mild moderate severe 
4. Would you say your stress level now was greater/milder/the SCIte as 
it was (a) at the mid-study point? 
(b) at the beginning of the study? 
APPENDIX 7 
DAILY DIARY 
Date ....•.•.•..•... II ••• I • II. II. Name ..•..•........•.................•.••.•.. 
Did you take any pills or medicine yesterday? 
If you did, what was the name of the medicine (or pill)? 
and the dose 
and the times taken 
Below are some statements concerning your feelings. please put a cross at the position 
which is closest to the way you felt yesterday. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
How happy were you? 
How 
How 
How 
How 
How 
How 
How 
happy I ~--------------------------------------------------------~I unhappy 
tired did you feel? 
exhausted I ~--------------------------------------------------------~I full of energy 
confident did you feel? 
confident I ~--------------------------------------------------------~I not confident 
tense or worried were you? 
very tense I ~------------------------------------------~-------------il calm & relaxed 
did you feel towards other people? 
friendly I ~----~----------------------------------------------~I hostile 
was your ability to concentrate? 
very poor I ~---------------------------------------------------------il very good 
was your muscular co-ordination? 
very good 
did you feel 
irritable 
I ~---------------------------------------------------------il very bad 
in yourself? 
~ ________________________________________________________ ~I nothing could 
upset me, 
unflappable 
Some more questions. Please tick the box that applies to you. 
(a) Were your breasts tender yesterday? 
(b) Did you feel bloated or swollen? 
(c) Were you constipated? 
(d) Did you have any food cravings? 
(e) Did you have a headache? 
(f) bid you have stomach cramps or pain? 
NO YES 
MILD MOD SEVERE 
Finally, is there anything else you would like to say about yesterday? please write 
on the back of this form. 
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